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ABSTRACT 
Renal failure in patients undergoing Aortic surgery is associated with a poor outcome. 
The shortcomings of serum creatinine for measuring renal function are well documented. 
We examined the value of alternative markers in diagnosing and predicting renal damage 
in patients undergoing abdominal aortic surgery and those exposed to intravascular 
contrast media. 
Cystatin C lacks some of the reservations associated with serum creatinine when used as 
a marker of glomerular filtration rate. The protease inhibitor alpha-glutathione S-
transferase (a-GST) is recovered in urine after injury to proximal tubular cells. Urine 
microalbumin is a marker of glomerular permeability. Together we used all four assays to 
detect and characterize the nature of renal injury after surgery and contrast exposure. 
Cystatin C had a marginally better sensitivity than serum creatinine at detecting baseline 
renal impairment. It also showed earlier changes in individual patients whose renal 
dysfunction deteriorated over time. The urinary markers showed an earlier significant rise 
after the onset of surgery when compared to serum markers, but only a-GST rose 
significantly after contrast exposure. Patients undergoing a supra-renal cross-clamp 
showed significantly higher a-GST levels (and not the other three markers) when 
compared to the infra-renal group. Cystatin C appears to have better sensitivity and 
specificity for predicting the need for dialysis in patients undergoing surgery. Peak serum 
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creatinine and cystatin C after contrast exposure show good correlation with peak values 
after surgery. 
Cystatin C is equivalent to and may be better than serum creatinine in detecting pre-
existing and deteriorating renal impairment. Although the urinary assays are earlier 
markers of renal injury, their clinical significance needs to be determined. Elevation in 
creatinine and cystatin C after contrast exposure parallel those after surgical intervention 
and may be helpful in selecting out high-risk patients prior to surgery. 
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Serum creatinine is a measure 
of glomerular filtration rate 
(GFR). It is freely filtered by 
the glomerulus and 10-40% 
may be secreted by the tubules. 
Serum cystatin C is a new 
marker of GFR that is freely 
filtered by the glomerulus and 
undergoes no tubular secretion. 
Urinary microalbumin is 





transferase (a-GST) is a protein 
specific to the cells of the 
proximal tubule. It is readily 
released into the urine after 
cellular injury 
Plate 1. Diagrammatic representation of the different parts of the nephron. SI and S2 
segments are part of the proximal convoluted tubule. S2 and S3 segments form part of the 
proximal straight tubule. (After Venkatachalam et al. 1978) 
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AIMS 
1. To determine the use of serum cystatin C, urine albumin and urine alpha-
glutathione S-transferase (a-GST) in predicting and detecting renal failure in 
patients undergoing aortic surgery and those undergoing intravascular contrast 
exposure. 
2. To determine the difference in the nature of renal injury in patients undergoing 
either a supra-renal or infra-renal aortic cross-clamp. 
3. To determine the difference in the nature of renal injury following aortic surgery 
compared with intravascular contrast exposure. 
4. To determine if the magnitude of renal injury after contrast exposure can predict 
the severity of post-operative renal dysfunction. 
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CHAPTER 1 BACKGROUND 
1.1 RENAL FAILURE IN VASCULAR SURGERY 
The prevalence of an elevated serum creatinine in a healthy subset of patients from the 
Framingham Study was 8.9% in men and 8.0% in women (Culleton et al. 1999). There 
are about 300 000 patients on renal replacement therapy in the USA (Luke 1998). About 
two thirds have diabetes or hypertension. There is also a higher prevalence of older age, 
dyslipidaemia and physical inactivity in this group. These are the typical traits of the 
vascular surgical patient. 
Secondary hypertension occurs early in many progressive renal diseases and exacerbates 
the vasculopathy. In an angiographic study of vascular ward admissions, it was found that 
34% had renal artery stenosis (Salmon et al. 1990). In the subgroup of patients with 
significant renal artery stenosis 93% had hypertension. Renovascular disease is thought to 
account for 12-14% of patients entering dialysis programmes (Mailloux et al. 1994). 
Surgical intervention inflicts major stresses on the kidney. Contrast media, anaesthetic 
agents, hypovolemia, cholesterol emboli and true ischaemic time can aggravate pre-
existing disease or result in new organ dysfunction. 
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1.2 PRECIPITATING FACTORS FOR RENAL FAILURE 
1.2.1 Renal cholesterol emboli 
Microembolisation of atheroma or cholesterol crystals from aortic or renal plaques can 
occur spontaneously or secondary to surgical or endovascular intervention. Cases 
following thrombolytic therapy have been reported (Ridker et al. 1989; Shapiro 1989). 
The kidney is the organ most frequently affected (Smith et al. 1981). Microscopic 
examination of the small arterioles reveal cholesterol clefts, the result of lipid dissolution 
during specimen preparation (Colt et al. 1988). Often the multitude of potential renal 
insults makes the diagnosis difficult unless the classical clinical signs are present. In a 
study of 52 patients with renal failure and histologically proven atheroembolism 
following angiography or cardiovascular surgery, only 50% had cutaneous signs of 
atheroembolism (Thadhani et al. 1995). Despite autopsy studies showing incidences of up 
to 77% of histological renal involvement in patients undergoing aortic aneurysm surgery, 
clinically significant disease is far less common (Smith, Ghose et al. 1981). The typical 
patient is a white male older than 60 years giving a history of hypertension, smoking and 
arterial disease, with a precipitating event followed by renal failure and signs of 
peripheral emboli (Scolari et al. 2000). 
Patients who have significant renal emboli have a dismal outlook but aggressive 
supportive therapy may be rewarded. 
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1.2.2 Drugs 
Nonsteroidal anti-inflammatory drugs (NSAIDS) and angiotensin converting enzyme 
(ACE) inhibitors normally have little effect on the kidneys (Lee et al.; Fredman et al. 
1999). When renal perfusion pressure is low, dilatation of the afferent glomerular 
arterioles by prostaglandins and constriction of the efferent glomerular arterioles by 
angiotensin II maintain intraglomerular pressures adequate for filtration (Abuelo 1995). 
Such situations are not uncommon in the vascular patient either due to a surgical insult or 
the presence of cardiac or renal artery disease. Glomerular filtration is subsequently 
impaired by the inhibition of prostaglandin synthesis by NSAIDS and of angiotensin II by 
ACE inhibitors. NSAIDS block the enzyme cyclooxygenase (COX), of which two 
isoforms exist, designated COXl and COX2 (Breyer et al. 2001). The deleterious effects 
on the kidney are mediated by the blockage of COX2. COX2-selective NSAIDS, whilst 
they have gastrointestinal-sparing effects, require the same caution as non-selective 
NSAIDS with regard to the kidney. Similar caution has been recommended with 
angiotensin II receptor antagonists, due to a similar pharmacological result as the ACE 
inhibitors (Saine et al. 1996). 38% of patients with newly diagnosed renal artery stenosis 
(RAS) were found to be on ACE inhibitors on presentation (Scoble et al. 1993). 
Potentially nephrotoxic antibiotics such as the anti-staphylococcal vancomycin and the 
aminoglycosides require dose adjustments in renal impairment. Frequent monitoring of 
blood levels is needed to avoid renal damage. 
* 
Volatile halogenated inhalational anaesthetic agents have been investigated for renal 
toxicity. Sevoflurane degrades into inorganic fluoride and 'Compound A' and has been 
shown to produce transient post-anaesthetic increase in urinary a-GST (Eger et al. 1997). 
A dose related response was demonstrated (Eger et al. 1997). Desflurane did not produce 
any rise in the urinary marker. In other studies low -flow sevoflurane and isoflurane (1 
1/min) did not produce any significant changes in urinary markers including a-GST 
(Kharasch et al. 1997) and high-flows (2 1/min) produced elevations in urinary markers 
but this was not considered clinically significant (Ebert et al. 1998). There is no 
consensus on the toxicity of sevoflurane, but desflurane and isoflurane (low-flow) appear 
not to have any significant effect on renal function. Both these agents undergo minimal 
metabolism. 
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1.2.3 Intravascular contrast media 
Contrast media reduce renal function by altering renal haemodynamics and by direct 
toxic effects on tubular epithelial cells (Tepel et al. 2000). Initially there is a transient 
increase in renal blood flow, followed by a prolonged vasoconstriction (Bakris et al. 
1999). The role of dopamine receptor agonists, adenosine agonists, saline, mannitol, 
frusemide, calcium channel blockers, atrial natriuretic factor, acetylcysteine and ACE 
inhibitors have been studied with varying success (Albert et al. 1994; Solomon et al. 
1994; Kapoor et al. 1996; Bakris, Lass et al. 1999; Gupta et al. 1999; Tepel, van der Giet 
et al. 2000). 
High osmolality ionic media were associated with a high incidence of renal injury and 
since the introduction of low osmolality non-ionic media there has considerable interest 
in its renal effects (Golman et al. 1985). Interpretation of the literature is made difficult 
by the numerous definitions of post contrast renal failure, either in the use of different 
markers, the magnitude of change in the markers and also the timing of the assays 
(Kinnison et al. 1989; Lautin et al. 1991; Barrett et al. 1993). The various media, dosages, 
routes of administration and different populations studied add to the difficulty. 
In patients with renal impairment, the incidence of acute renal failure after non-ionic 
iohexol ranges from 5.5% (increase in creatinine >50% or >1.0mg/dl) and 11.8% 
(increase in creatinine >0.5mg/dl) to 15% (increase in creatinine >1.0mg/dl) (Gomes et 
al. 1989; Taliercio et al. 1989; Rudnick et al. 1995). In patients with a normal serum 
creatinine a 4 - 10% incidence of acute renal failure has been quoted (increase in 
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creatinine >25%) (Jakobsen et al. 1994; Rosovsky et al. 1996). However, in a similar 
patient group, there was no change in GFR measured by Cr-51 -EDTA after iohexol 
(Tornquist et al. 1984). The frequency of nephrotoxicity between low- and high-
osmolality contrast media has been shown to be similar (Gomes, Lois et al. 1989; 
Kinnison, Powe et al. 1989; Moore et al. 1992) unless renal impairment with or without 
diabetes mellitus is present (Harris et al. 1991; Barrett and Carlisle 1993; Rudnick, 
Goldfarb et al. 1995). 
Peritoneal and haemodialysis has been shown to be effective methods of eliminating the 
non-ionic contrast medium iohexol after angiography (Moon et al. 1995; Furukawa et al. 
1996), however in patients with moderate renal impairment this has not been shown to 
reduce the incidence of nephrotoxicity (Lehnert et al. 1998; Sterner et al. 2000). 
Carbon dioxide digital angiography has the advantages of being low cost, producing 
minimal discomfort, using smaller catheters, having no allergy risk and as it is excreted 
by the lungs in one circulation, allowing unlimited total volumes to be used without any 
apparent nephrotoxicity. Potential neurotoxicity, poor image quality and the phenomenon 
of 'vapour lock' (where blood flow is effectively prevented by too rapid injection of 
CO2) are some disadvantages (Hawkins et al. 1994). 
The use of the oral antihyperglycaemic agent metformin carries the risk of lactic acidosis. 
It undergoes renal excretion and therefore its use in renal disease is cautioned (Scheen 
1996). It is also contra-indicated in pregnancy, peri-operatively and in liver, respiratory 
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and severe cardiac disease (Chan et al. 1999). Recently, there have been concerns about 
lactic acidosis after the use of intravascular iodinated contrast agents and in 1996 the 
Royal College of Radiologists published advice supporting the manufacturer that 
metformin should not be used in the 48 hours before or after the administration of 
intravenous contrast medium. Two subsequent studies reviewed the literature and 
concluded that in almost all cases of lactic acidosis there was pre-existing renal 
impairment or other contraindications to the use of metformin (Nawaz et al. 1998; 
McCartney et al. 1999). There has been only one reported case of lactic acidosis 
following intravenous contrast in a patient with normal renal function. Both studies 
conclude that it is safe to give intravascular contrast to patients on metformin, provided 
their renal function is normal. 
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1.3 POST OPERATIVE RENAL FAILURE 
1.3.1 Introduction 
In a prospective study of 1566 patients performed by the Joint Vascular Research Group 
in the United Kingdom (JVRG), the incidence of post operative renal failure in vascular 
patients varied from 45.5% (thoracoabdominal aneurysm) to 0.82% (carotid 
endarterectomy) (unpublished data). The definition of acute renal failure varies 
considerably in the literature. Definitions include 
> > 1 mg/dl increase in serum creatinine 
> creatinine level > 2.0mg/dl 
> creatinine level > 3.0 mg/dl 
> doubling of the serum creatinine and 
> the need for dialysis (Novis et al. 1994; Kashyap et al. 1997) 
The interpretation is confounded by the reporting of creatinine in units of either mg/dl or 
|amol/L (44 u.mol/L is equivalent to 0.5 mg/dl). In general, a rise of > 20% in serum 
creatinine will identify most patients whose creatinine clearance falls by more than 50% 
(Charlson et al. 1989). In the present study, we have used a rise > 25% to be significant. 
1.3.2 Thoracoabdominal aneurysms 
The mortality following renal failure complicating thoracoabdominal aneurysm surgery is 
50%(unpublished data). In a review of their series of thoraco abdominal aneurysms, Safi 
et al. found a post operative acute renal failure rate of 17.5% and a mortality rate in this 
group of 49% (Safi et al. 1996). Other studies show renal failure incidences of 14% 
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(mortality 42%) (Schepens et al. 1994) and 25% (mortality 44%) (Godet et al. 1997) and 
10% (Cambria et al. 1997). The development of post-operative renal failure is a 
significant risk factor for death. Furthermore peri-operative factors associated with post-
operative renal failure were preoperative creatinine > 2.8 mg/dl, visceral perfusion, left 
renal artery reattachment and simple cross clamp technique (Safi, Harlin et al. 1996), age 
(increased risk 1.2 per year) and pre-operative creatinine (increased risk 1.01 per 1 
pmol/L) (Schepens, Defauw et al. 1994), age > 50 years, preoperative creatinine > 120 
umol/L, left kidney ischaemia > 30 minutes, transfusion of packed cells or cell saved 
blood > 5 units (Godet, Fleron et al. 1997), pre-operative creatinine >1.5 g/dl (Kashyap, 
Cambria et al. 1997). Pre-operative renal impairment is also a significant predictor of 
mortality (Gilling-Smith et al. 1995; Cambria, Davison et al. 1997). 
1.3.3 Abdominal Aortic Aneurysms 
In patients undergoing repair for non-ruptured abdominal aortic aneurysms, the incidence 
of post-operative renal failure is much lower. The Canadian aneurysm study showed a 
renal failure rate of 5.4% and a dialysis rate of 0.6% (Johnston 1989). The mortality 
associated with renal failure was 28%. Other authors quote renal failure rates of 7% up to 
18%o (Diehl et al. 1983, Joseph et al. 1989). The rates of patients requiring post-operative 
dialysis has been reported at 1.2% up to 7% (O'Donnell et al. 1989; Holland et al. 1998). 
Again, elevation of the pre-operative creatinine is associated with the development of 
post-operative renal failure and is also a factor linked to peri-operative mortality. In our 
institution only age and pre-operative creatinine were independent pre-operative risk 
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factors for mortality on multivariate analysis (unpublished data). Schepens et al. found 
similar results for thoracoabdominal aneurysms (Schepens, Defauw et al. 1994). 
Emergency surgical repair of a ruptured abdominal aortic aneurysm carries an overall 
mortality of 50% (Drott et al. 1992). In a single centre study, the mortality rate of 65 
repairs complicated by acute renal failure was 75%. Of the survivors, the majority had 
irreversible renal impairment. Only 1 patient required long term dialysis. The results of 
18 patients requiring renal support after ruptured aortic aneurysm showed eleven 
survivors (Gordon et al. 1994). By 3 months eight were independent of dialysis. 
In our tertiary vascular practice, only 3.9 % of patients overall required renal replacement 
therapy (unpublished data). The in-hospital mortality associated with post-operative 
renal failure was 60%. Only 1 of the 1253 patients studied required long-term renal 
replacement therapy, affirming that complicated vascular surgery does not appear to 
place a significant long-term burden on renal services. 
Patients with established end stage renal disease (ESRD) on haemodialysis also present 
for surgical management of their aortic aneurysms. A French study of 33 such patients 
operated on from six to eight hours after dialysis had a postoperative mortality of 9% 
(Lacombe 1998). However the long-term survival was 43% at five years and 11% at ten 
years. 
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Aortic reconstruction after renal transplantation places the renal allograft at risk for 
ischaemic damage. Intraoperative manoeuvers to maintain renal perfusion include 
extracorporeal pump oxygenation, temporary axillofemoral bypass, aortofemoral shunt 
and an indwelling shunt through the graft (Kashyap et al. 1999). For thoracoabdominal 
aneurysm repair we have used left atrio-femoral bypass to maintain flow to the allograft 
during aortic cross-clamp. 
1.3.4 Endovascular Aneurysm Repair 
Despite attempts to avoid the mortality and morbidity associated with open aneurysm 
repair, endovascular repair has not eradicated the postoperative complications. Indeed a 
whole new set of complications specific to this technology has now arisen. With regard to 
renal dysfunction, patients with normal preoperative renal function have a 6% risk of 
postoperative renal dysfunction after abdominal aortic aneurysm repair (Walker et al. 
1998). About 44% of this subgroup will die. For patients with pre-operative renal failure, 
the peri-operative mortality is 27%. 
1.3.5 Carotid Endarterectomy 
In an analysis of our experience over a two-year period of 176 patients undergoing 
carotid endarterectomy, none had preoperative renal impairment and none required post-
operative renal support (unpublished data). Nationally in the UK, the incidence of post-
operative renal failure following carotid endarterectomy was 0.18% (unpublished JVRG 
data). In a multicentre risk assessment study of 9795 carotid endarterectomies, renal 
failure was significantly associated with increased operative stroke and mortality rates 
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(Plecha et al. 1993). In a smaller study the incidence of postoperative stroke and death 
was significantly higher (43%) in patients with severe chronic renal insufficiency 
(creatinine > 2.9 mg/dl) than in those with normal renal function (6% and 1%) (Rigdon et 
al. 1997). Complications in patients with mild renal insufficiency (creatinine 1.5-2.9 
mg/dl) were not significantly different from the control group. Another report looking at 
patients with mild renal impairment (creatinine > 1.5 mg/dl) showed significantly higher 
stroke and death rates compared to those with normal renal function(Hamdan et al. 1999). 
A recent publication challenges this difference in outcome for renal patients. In a study of 
a mixed group of chronic renal insufficiency (32) and end stage renal disease (ESRD) 
(19), the perioperative stroke-mortality rate was similar to the control group (2.0% vs. 
2.6%). (Sternbergh et al. 1999). Operations were performed for asymptomatic as well as 
symptomatic disease. However the 4-year survival rate was 54% for chronic renal 
insufficiency and only 12% in ESRD. The poor long-term survival may well negate any 
stroke prevention benefits accrued through surgery, which dictate that the patients be 
expected to survive at least 2 years (Cina et al. 2000). 
1.3.6 Infra-inguinal Vascular Disease 
In our experience, infra-inguinal bypass is associated with a 5% incidence of renal 
failure. Other studies showed that 16% of patients with peripheral vascular disease had 
severe renal artery stenosis and about a third of this subgroup died from cardiac or renal 
complications post operation (Salmon and Brown 1990). Reperfusion syndrome 
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following revascularisation of the acutely ischaemic leg carries a high incidence of renal 
failure (Defraigne et al. 1998). 
It is not uncommon for patients with ESRD to present to the vascular surgeon with a 
critically ischaemic leg. Cardiovascular disease is the leading cause of death in ESRD 
and peripheral vascular disease is a leading cause of morbidity (Holley 2000). The overall 
mortality is 41-48% at 2 to 3 year follow up (Marcelli et al. 1996; Peltonen et al. 1998). 
The shortened life expectancy of this group of patients affects the benefits gained from 
screening for vascular disease. 
Results of intervention show satisfactory limb salvage rates in survivors. The mean limb 
salvage rate at 2 years was 72% (range 52-94%) (Isiklar et al. 1997). Infrageniculate 
reconstruction led to a subsequent higher quality of life. Perioperative mortality rates 
vary from 6-10% (Harrington et al. 1990; Johnson et al. 1995). At age 59 the expected 
remaining lifetime for dialysis patients is 4.3 years (3 years if diabetic as well) (Mailloux, 
Napolitano et al. 1994). Intervention for claudication should be carefully weighed against 
the poor long-term survival. 
Primary amputation should be considered for forefoot gangrene. The amputation rate in 
diabetics with ESRD was 10 times that of the diabetic population at large (Eggers et al. 
1999). Two thirds died within 2 years following amputation. 
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Interpretation of results relating to infrainguinal bypass surgery in general is made 
difficult by the failure to stratify patients according to symptoms, extent of bypass and 
conduit. The small numbers of patients in individual series with ESRD makes this 
subgroup even more difficult to interpret. 
1.3.7 Renal Artery Stenosis 
The true prevalence of Renal Artery Stenosis (RAS) in the general population is not 
known. Numerous studies have defined the prevalence in selected populations. Early 
autopsy studies found rates of significant (>50%) stenosis of 5% in patients < 64years 
old, 18% in patients 65 to 74 years old and 42% in patients >75 years old (Schwartz et al. 
1964). About 50% were bilateral. During aortography for concurrent vascular disease the 
incidence of significant RAS in various studies was 16-28% for aortic disease, 14-30% 
for coronary artery disease and 22-45% for peripheral artery disease (Conlon et al. 2000). 
The natural history of severe stenosis has been assessed, looking at both progression of 
stenosis and the reduction in renal size. Rates of progression of stenosis for patients 
undergoing coronary angiography at one and six years were 6.5% and 25% respectively 
(Crowley et al. 1998). Overall about 50% of patients will progress and 16% will occlude 
(Schreiber et al. 1984). About 40% of patients with stenosis > 75% will progress to 
occlusion. Reduction in renal size >10% occurred in 37% of patients with renovascular 
hypertension (Dean et al. 1981) and 26% of patients with significant RAS had a reduction 
in renal size >lcm after a mean of 14 months follow up (Strandness 1994). Progressive 
deterioration in renal function has also been shown, with a creatinine rise from a mean of 
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1.4 mg/dl to 2.0 mg/dl over 39 months (Chabova et al. 2000). In their prospective study at 
44 months Dean et al. showed that 19 of 41 patients had a more than 25% increase in 
serum creatinine (Dean, Kieffer et al. 1981). 
The long-term survival for patients with ischaemic nephropathy is poor. Scoble et al. 
found a 2-year mortality rate of around 25% with intervention and 30% without (Scoble, 
Sweny et al. 1993). Harden and colleagues had a mortality rate around 55% two years 
after renal artery stenting (Harden et al. 1997). Work done by the author show, after a 
mean follow up of 2.4 years, mortality rates of 33% with intervention and 29% without 
(Pillay et al. 2002). After a mean of 39 month follow up, the Mayo clinic found a 
mortality of 28% (unrelated causes) in patients with stenosis > 70% (Chabova, Schirger 
et al. 2000). 
Overall outcome after intervention (surgery, angioplasty and stenting) reveal a 
distribution between improvement, no change and deterioration in renal function. Renal 
function improves in 22- 65% and deteriorates in 6 - 48% (Alcazar et al. 2000; Safian et 
al. 2001). 
More important than the static effect on creatinine or GFR is the effect on the rate of 
decline in GFR or increment in creatinine. It is against this statistic that the success or 
failure of surgical or minimally invasive intervention should be judged. The mean slope 
of the reciprocal creatinine plot over time in 23 patients with RAS was -4.34 1/umol/day 
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(Harden, MacLeod et al. 1997) and -0.0079 dl/mg/month in another 33 patients (Watson 
et al. 2000). 
Large trials are required to identify those patients who will benefit from intervention i.e. 
whose rate of deterioration in renal function will improve. At the same time we need to 
be able to identify patients with poor long-term survival prospects, who do not survive 
long enough to reap the benefits of any intervention. 
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CHAPTER 2 ASSESSING RENAL FAILURE 
2.1 INTRODUCTION 
The glomerular filtration rate (GFR) is the standard measure of renal function. It is 
defined as the volume of plasma that can be completely cleared of a particular substance 
by the kidney in a unit of time. The most accurate method of measuring GFR is by inulin 
clearance. It is freely filtered in the kidney and does not undergo any metabolism, 
secretion or absorption. Inulin is expensive and the laboratory assay is difficult and 
expensive. 
Other exogenous substances such as iohexol, 51Cr-EDTA, 99mTc-labeled DTPA or 125I-
labeled iothalamate are equally labour-intensive. Thus, the measurement of endogenous 
substances to estimate GFR is common. The properties of an ideal substance should 
include release into the blood stream at a constant rate, free filtration by the glomerulus, 
no reabsorption or secretion by the renal tubules, and exclusive elimination via the 
kidneys (Laterza et al. 2002). 
Initially blood urea was used but due to the large proportion that undergoes passive 
reabsorption, serum creatinine has become the most commonly used serum marker of 
renal function. Other endogenous markers include the low molecular weight proteins oti-
microglobulin, p2-microglobulin and retinol binding protein. These have largely been 
abandoned due to the influence of non-renal factors on their circulating concentrations 
(Grubb et al. 1985; Grubb 1992). 
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Recovery of enzymes and other proteins in the urine was recognised early on as a marker 
of renal disease. The availability of newer assays to determine renal dysfunction allows 
discrimination between falling GFR and tubular dysfunction (Porter 1994; Scherberich et 
al. 1994). Further assessment of various urinary enzymes and low molecular weight 
proteins allows localisation of injury to different parts of the nephron. 
Criteria were outlined for selecting potentially useful markers (Gonick et al. 1973). N-
Acetyl-P-D-glucosaminidase (NAG) is a tubular enzyme that has been studied as a 
marker of tubular injury (Kunin et al. 1978). It has a high molecular weight to not be 
ordinarily filtered and is thought to arise from damage to the S3 segment and the distal 
nephron. Alanine aminopeptidase (AAP) appears to originate from the proximal tubule 
(Porter 1994). The wide variability of results and the influence of non-renal factors on 
some of these markers have limited their use (Jung 1994). 
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2.2 CREATININE 
Because creatinine is freely filtered by the glomerulus, the serum creatinine has been 
used to estimate GFR. Creatinine levels are proportional to muscle mass (which is 
determined by age, body weight and sex), dietary intake, extrarenal clearance and tubular 
secretion. Furthermore, creatinine levels only start to rise after GFR has dropped by 50%, 
mainly because of the effects of tubular secretion (Watson, Hadjipetrou et al. 2000). 
There is now an increasing realisation that serum creatinine is an inadequate measure of 
the absolute level of renal function in the individual patient. 
Despite this, many authors believe that the rate of decline in the reciprocal of serum 
creatinine accurately reflects the rate of loss of renal function. Furthermore it has been 
noted that there is a linear decline over time of the reciprocal of serum creatinine. 
Therefore, any change in slope of this linear decline over time has been interpreted to 
indicate a change in the rate of deterioration. However the change in slope is also affected 
by the rate of creatinine generation and extrarenal excretion. Studies demonstrating the 
linear decline had carefully selected their patients and had low correlation coefficients for 
their linear estimates (Levey et al. 1988). Nevertheless, the effect of intervention on the 
slope of the reciprocal of creatinine over time will continue to be used as a measure of 
success in clinical studies(Watson, Hadjipetrou et al. 2000). The ASTRAL trial, for 
example, has as a measure of its primary endpoint, the change in the slope of the 
reciprocal creatinine plot (2000). 
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24-hour creatinine clearances are fraught with errors of collection and because of the 
contribution of tubular secretion, generally overestimate GFR. Theoretically, because 
cimetidine competes with creatinine for tubular secretion, it decreases the secretion of 
creatinine by tubular cells. Its oral administration improves the accuracy of creatinine 
clearance measurements by decreasing the error caused by tubular secretion (Toto 1995). 
Formulae have been developed to overcome the error from the contribution of the 
extrarenal determinants of serum creatinine. The Cockcroft-Gault formula, correcting 
serum creatinine for sex, age and weight, is the most consistently used and widely 
applicable (Cockcroft et al. 1976; Toto 1995) (see APPENDIX A). The estimates of GFR 
are most applicable in the range of 10-100 ml/min. 
Studies looking at the biological variation in serum creatinine have calculated a value of 
14% of the mean value in health (86 umol/1) (Keevil et al. 1998). Hence a change of only 
12 umol/1 is highly significant in the same individual. 
The definition of renal failure varies considerably and we have used cut-off values of a 
more than 25% rise over baseline or a more than 44 umol/1 rise. These are well above the 
biological variation described. 
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2.3 CYSTATIN C 
A promising new marker for estimating GFR is Cystatin C. It is a non-glycosylated 13 
kD basic protein that is a member of the cystatin superfamily of cystein protease 
inhibitors (Grubb et al. 1982; Barrett et al. 1984). It is produced by all investigated nucleated 
cells (Lofberg et al. 1979). The structure of its gene and promoter has been determined. 
The gene is of the housekeeping type, which is compatible with a stable production rate 
by most cells (Abrahamson et al. 1990). The production rate is unaltered in inflammatory 
conditions. It is freely filtered in the renal glomeruli and almost completely reabsorbed 
and catabolised by the proximal tubular cells (Grubb 1992; Tenstad et al. 1996). The low 
molecular weight and its stable production rate strongly indicate that the blood serum 
concentration of this protein is mainly determined by the glomerular filtration rate (GFR). 
The serum concentration of cystatin C has been shown to be at least as good an indicator 
of GFR as the serum concentration of creatinine (Grubb, Simonsen et al. 1985; Simonsen et 
al. 1985). 
Most studies suggest that serum cystatin C is independent of gender, however one study 
suggested that concentrations were lower in women than in men (Pergande et al. 1993). 
This study using the ELISA technique reported significantly higher serum concentrations 
than others. Some studies had utilised the technique of enzyme amplified single radial 
immunodiffusion (SRID). A rapid and automated procedure for the quantification of 
serum cystatin C based upon the latex particle enhanced immunoturbidmetric assay 
(PETIA) technique has been produced (Newman et al. 1995). 
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There was no significant difference in values between males and females. This was 
confirmed by other investigators (Randers et al. 1998). In 1997 Finney et al. described a 
particle-enhanced immunonephelometric immunoassay (PENIA) (Finney et al. 1997). 
This fully automated assay showed good intra- and interassay precision, as well as 
agreement with the previously described PETIA. No difference was found between 
samples analysed immediately and those stored at -20°C. 95% Reference intervals for 
serum cystatin C concentration were determined to be 0.51-0.98 mg/1. For women the 
interval was 0.49-0.94 mg/1 and men 0.56-0.98 mg/dl. Because of the small difference it 
was suggested that a single range for all adults less than 50 years, without adjustment for 
body surface area, be used. (This version of the latex immunoassay was used for this 
study) 
These enable a shorter reaction time and provide a result in 15 minutes. In addition the 
assay can be performed on the same instruments routinely used for assessment of serum 
creatinine by the Jaffe method(Newman, Thakkar et al. 1995; Keevil, Kilpatrick et al. 
1998). 
Cystatin C offers greater sensitivity in detecting an abnormal GFR with equivalent 
specificity and overall better diagnostic efficiency (Newman et al. 1994; Newman, Thakkar 
et al. 1995). With renal disease there was significantly better correlation of Cystatin C to 
GFR (51Cr-EDTA) (r = 0.80) than serum creatinine (r = 0.5). It has also been 
demonstrated that Cystatin C is an earlier indicator of mild renal failure and is more 
likely to be abnormal with a decreased GFR than serum creatinine (Fliser et al. 2001). 
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Using a lower reference range of GFR to be 72 ml/min/1.73m2, it was demonstrated that 
a cystatin C result of greater than or equal to 1.25mg/l had a sensitivity and specificity for 
diagnosing renal impairment of 71.4% and 95.1% respectively. A serum creatinine of 
greater than 110 u.mol/1 demonstrated results of only 52.4% and 91.8% respectively 
(Newman, Thakkar et al. 1995). Besides rising earlier, Cystatin C has been shown to also 
rise to a greater extent than serum creatinine for lower GFR. This makes cystatin C a 
potentially better marker for detecting renal impairment than serum creatinine. 
We used a baseline cystatin C > 1.24 mg/1 to denote pre-existing renal impairment. 
The biological variation of cystatin C has been calculated at 37% of the mean reference 
value and would require a difference of 0.24 mg/1 to be regarded as significantly different 
(Keevil, Kilpatrick et al. 1998). This suggests that cystatin C may not be as sensitive as 
serum creatinine in for detecting changes within the same individual. 
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2.4 ALPHA GLUTATHIONE S-TRANSFERASE 
Alpha glutathione S-transferase (a-GST) is a cytosolic protein highly specific for the 
cells of the proximal renal tubules (Campbell et al. 1991). It is part of the family of 
glutathione S-transferases and plays a role in protecting cells by using reduced 
glutathione to conjugate or reduce many different reactive electrophiles. This usually 
inactivates these electrophiles and facilitates their excretion in urine or bile (Seidegard et 
al. 1997). It is found in high concentrations and is readily released from injured cells into 
the urine. 
Alpha GST is found in the proximal renal tubule while pi GST is found in the distal 
tubule (Harrison et al. 1989). Studies have shown that the straight portion of the proximal 
tubule (the S3 segment) is the most susceptible to ischaemic and toxic injury 
(Venkatachalam et al. 1978; Torhorst et al. 1982). Alpha GST release has been shown to 
follow the time course of proximal tubular necrosis as proven by histological changes 
(Bass et al. 1979). Urinary alpha GST has been used as a sensitive marker of proximal 
tubular damage after exposure to nephrotoxic insults (Sherman et al. 1984; Eger, Koblin et 
al. 1997) Increased recovery of alpha GST has been documented after exposure to 
iodinated contrast media despite no rise in serum creatinine (Sherman, Feinfeld et al. 
1984). This was dose related and occurred within 36 hours of contrast exposure. 
Recently published data from a pilot study of 8 patients in Newcastle, UK showed that 
alpha GST provided an early indication of postoperative renal injury (Cressey et al. 
2002). In patients undergoing infra-renal aortic aneurysm repair all patients with 
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postoperative renal dysfunction (using creatinine) had elevations in alpha GSTxreatinine 
at one and three hours after removal of the aortic cross clamp. Peak a-GSTxreatinine 
ratios were significantly associated with the peak % increase in serum creatinine. 
Alpha GST is measured by a quantitative enzyme immunoassay and at a 1/2 dilution has 
a recordable range of 0-80 fig/1. The manufacturer's reference range is < 11.1 jj.g/1 and 
interassay variation is up to 9.8% (Biotrin International, Dublin, Ireland). 
No reference range is available for urine GSTxreatinine ratio, though this correction 
allows spot samples to be taken, avoiding the problems associated with timed samples. 
This correction has been used before (Cressey, Roberts et al. 2002). 
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2.5 URINE ALBUMIN 
Microalbuminuria describes pathological albuminuria in the 30-200 mg/1 range, which is 
undetectable by chemical dip sticks (Watts et al. 1988). 
Increased urine albumin may be due to increased glomerular filtration or to decreased 
tubular absorption. Increased glomerular permeability is best assessed by selectivity 
studies measuring different molecular weight protein markers in the urine. Urine albumin 
reflects primarily glomerular permeability, whereas total protein reflects a combination of 
permeability, tubular leakage, tubular secretion, and normal protein shed in the urine 
(Newman et al. 2000). Dividing by urine creatinine not only improves the intra-individual 
variation in albumin but also corrects for variations in urine flow. 
Surgery-induced microalbuminuria occurs within 30 minutes of operation (Fleck et al. 
1985). A relationship between high urinary albumin to creatinine ratios and subsequent 
pulmonary dysfunction has been shown in infra-renal aortic aneurysm repair (Smith et al. 
1994). Changes in glomerular permeability probably reflect changes in systemic vascular 
permeability. Urine albumin measurement alone has been used as an assessment of 
increased permeability (Gosling et al. 1994; Pallister et al. 1997). Reperfusion injury with 
increased vascular permeability would therefore result in a significant increase in 
microalbuminuria. 
Proteinuria has been studied in assessing potential nephrotoxicity of contrast agents. 
Massive albuminuria has been reported with the older media and very much less with the 
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LOM (Tornquist et al. 1985). The phenomenon is transient but must reflect glomerular 
and/or tubular damage. 
Reference values for daytime ambulatory urine albumin range between 0.9-29.6 mg/1 and 
for albuminxreatinine ratio between 0.1-2.3 mg/mmol (Watts, Morris et al. 1988). Intra-
individual variation of urinary albumin: creatinine ratios in healthy subjects range 
between 52% and 111% (Watts, Morris et al. 1988; Newman, Pugia et al. 2000). 
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CHAPTER 3 MATERIALS AND METHODS 
This was a prospective longitudinal observational study. 
3.1 STUDY SETTING 
Patients presenting for Vascular Surgical management at the Regional Vascular Unit at St 
Mary's Hospital were recruited for the study between September 2000 to August 2001. St 
Mary's Hospital NHS Trust is a tertiary referral centre for Vascular Surgery in the United 
Kingdom. Ethical approval to conduct the study was obtained from the St Mary's Local 
Research Ethics Committee and the University of Natal Research Ethics Committee. 
Serum Cystatin C and all the urinary assays (urine creatinine, albumin and a-GST) were 
performed at the South West Thames Institute for Renal Research, which is affiliated to 
the St Helier NHS Trust. 
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3.2 PATIENT SELECTION 
Patients were recruited at the Vascular Surgery Outpatient Clinic or on admission to the 
Vascular Surgery Ward. Informed consent (see Appendix B) was obtained after patient 
counselling (see Appendix C and D). No honorarium was paid for participation in the 
study. 
Inclusion criteria: 
• All patients undergoing elective intravascular-enhanced contrast radiology for 
vascular disease. 
• All patients undergoing infra-renal and juxta-renal aortic aneurysm repair. 
• All patients undergoing aorta-bifemoral bypass for aorto-iliac occlusive 
disease. 
Exclusion criteria: 
• Emergency surgery. 
• Patients undergoing endovascular procedures. 
• Patients in end stage renal failure. 
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33 DATA COLLECTION 
There was no deviation from the routine pre-operative and post-operative management of 
patients except that additional blood specimens were taken at the time of routine 
venepuncture and from existing arterial lines, and mid-stream urine was collected pre-
operatively and from indwelling urinary catheters post-operatively. 
Demographic details were recorded on a pro forma data sheet and stored electronically on 
FileMaker Pro 4.0 (Claris) (see Appendix E). Further note was made of Angiography and 
CAT scan details including type and volume of contrast and operative details including 
operative time, renal ischaemia time, the use of cardiac bypass, volume of blood 
transfusion and type of renal revascularisation. The study data was only accessible to the 
primary investigators in the study. 
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3.4 SPECIMEN PROCESSING 
Five millilitres of blood and 10 ml of urine specimens were taken at the following time 
points: 
Contrast exposure (C): 
• Pre contrast (CI) 
• Day-1 post contrast (C2) 
• Day-7 post contrast (C3) 
Surgery (T): 
• Pre-operation (Tl) 
• Prior to aortic cross-clamp (T2) 
• Prior to lower limb reperfusion (T3) 
• 2-hours after lower limb reperfusion (T4) 
• Day-1 post-operation (T5) 
• Day-4 post-operation (T6) 
• Day-7 post-operation (T7) 
Serum creatinine assays were performed as part of the routine intensive care 
management. 
Clotted blood was centrifiiged, separated and then 2 x 1ml aliquots stored at -20 degrees 
Celsius. Two 1 ml urine specimens were frozen at -20 degrees Celsius. After addition of 
a stabilizing buffer (4:1) a further 2 x 1 ml urine specimens were frozen at -20 degrees 
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Celsius. Samples were initially processed and stored in the Academic Surgical Unit 
Laboratory at St Mary's Hospital. 
Samples were transported in batches to be processed at the South West Thames Institute 
for Renal Research, Surrey. The four anylates assessed were 
- Serum cystatin C (PENIA) 
- Urinary alpha glutathione S-transferase (alpha-GST) (Biotrin NEPHKIT™-
ALPHA Human GST-Alpha, Biotrin Int. Ltd., Ireland) 
- Urinary microalbumin and urinary creatinine. 
Serum creatinine results were obtained by routine processing through the St Mary's 
Hospital biochemistry laboratory. 
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3.5 RESULTS CORRECTION 
Due to the variation in urine flow and hence the concentration of the urinary markers, 
urinary GST and urinary albumin were corrected for by dividing the assay result by the 
result of urine creatinine assayed at the same point. 
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3.6 PROCEDURE DESCRIPTIONS 
3.6.1 Intravascular contrast-enhanced radiological investigation 
All patients had baseline serum creatinine and coagulation studies done. Patients with 
serum creatinine > 120 umol/l had an intravenous line placed the night before and a litre 
of 0.9% saline infused over 12 hours. All studies were performed using Iohexol, a low-
osmolar, non-ionic agent. Urine output was monitored for the 24 hours post contrast 
exposure. 
3.6.2 Open aortic surgery 
All operations were done under general anaesthesia with an epidural catheter and 
indwelling Foley catheter placed in theatre. Anaesthesia was maintained by desflurane or 
isoflurane inhalation. All patients were given an intravenous dose of vancomycin of 
500mg on induction of anaesthesia. This was repeated for three days thereafter. Trough 
levels were checked prior to administering the subsequent doses. 
'Renal' dopamine was defined as the use of a dopamine infusion at 3 |a,g/kg/min. 
Frusemide was infused at a rate of 0.5 - 1.0 mg/min in some patients. Significant intra-
operative hypotension was defined as a sustained systolic blood pressure less than 70 
mmHg requiring either the infusion of colloid or an inotrope (dobutamine). The decision 
in the use of anaesthetic agent, diuretic or inotropic agent was made individually by one 
of three consultant vascular anaesthetists. 
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Post-operatively patients were nursed in a high-dependency unit or ICU. Management 
was dictated by the individual patient responses and was along standard protocols for 
post-operative care. 
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CHAPTER 4 RESULTS FOR PATIENTS UNDERGOING 
VASCULAR SURGERY WITH AN AORTIC CROSS 
CLAMP 
4.1 PATIENT DEMOGRAPHIC DATA 
BACKGROUND 
Thirty-five patients underwent aortic surgery; 29 for aortic aneurysms and 6 for aortic 
occlusive disease. There were 7 females and the median age was 71 years (Table I). The 
median Cockcroft-Gault calculated creatinine clearance at baseline was 58.7 ml/min. The 
median baseline creatinine clearance was not significantly different between the patients 
with aortic aneurysmal and occlusive disease. 
INTRA-OPERATIVE DATA 
Twenty-six operations involved an infra-renal aortic cross-clamp and 9 were performed 
with a supra-renal cross-clamp (Table II). Statistical significance between the supra-renal 
and infra-renal group was examined using the Fisher's Exact Test for the nominal 
variables and Mann-Whitney Test for the continuous variables. The proportion of patients 
with ischaemic heart disease was significantly higher in the group undergoing an infra-
renal aortic cross-clamp (P = 0.036). All patients undergoing supra-renal aortic cross-
clamp had an intra-operative infusion of dopamine (P = 0.015). 
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Two patients underwent left renal vein ligation to improve surgical access for the 
proximal anastomosis. Their calculated creatinine clearances were 70 and 61 ml/min 
respectively. The former patient had a rise in Cystatin C greater than 37%. No other 
adverse outcome (as defined for this study) was recorded in either patient. 
DIALYSIS 
A total of five patients needed dialysis after surgery. Three patients had aneurysmal 
disease and 4 underwent infra-renal aortic cross-clamp. Two patients requiring dialysis 
died. A more detailed analysis of this group is described in Section 4.3. 
DEATHS 
Overall 3 patients died. Two had undergone a supra-renal procedure for aneurysmal 
disease and had calculated creatinine clearances of 47 and 40 ml/min respectively. The 
former died of multi-system organ failure after a prolonged period of dialysis-
dependence, and the latter died intra-operatively from massive intra-operative 
haemorrhage. The third patient underwent surgery for aortic occlusive disease. She died 
from complications after developing colonic ischaemia, necessitating a re-look 
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Table I. Pre-operative data for 35 patients undergoing aortic surgery and stratified by 
supra- or infra-renal aortic cross-clamp. Continuous variables are median values. 
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Units Packed Cells 
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Intraoperative urine flow 
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Anaesthetic time (min) 
Surgery time (min) 
Lower limb ischaemic 
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Table II. Intra-operative data for 35 patients undergoing aortic surgery and stratified by 
supra- or infra-renal aortic cross-clamp. Continuous variables are median values. (* P = 
0.015, Fisher's Exact Test) 
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4.2 RENAL FAILURE DIAGNOSIS 
4.2.1 Sensitivity and specificity of baseline serum creatinine and serum cystatin C in 
diagnosing pre-existing renal dysfunction. 
INTRODUCTION 
Serum creatinine values above 120 umol/1 are considered abnormal. It is well described 
that creatinine is an insensitive marker for renal dysfunction as it only starts to rise after a 
50% drop in GFR (Section 2.2). 
Reference values serum cystatin C range from 0.51 - 0.98 mg/1 (Section 2.3). The 
sensitivity and specificity for diagnosing renal failure using a definition of GFR < 72 
ml/min/1.73 m2 (Cr-EDTA) has been shown to be better using cut-off levels of cystatin C 
>= 1.25 mg/1 (71.4% and 95.1% respectively) versus serum creatinine >= 110 umol/1 
(52.4% and 91.9% respectively). 
For this study we used cut-off points of serum creatinine > 120 umol/1 and a serum 
cystatin C > 1.24 mg/1. 
We investigated the sensitivity and specificity of the two assays at different cut-off points 
using a definition of calculated GFR (Cockcroft-Gault) < 72 ml/min. 
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METHODS 
Receiver operating characteristic (ROC) curves were constructed using baseline serum 
creatinine and baseline serum cystatin values with the outcome of calculated creatinine 
clearance < 72 ml/min. Cut-off points to maximize the associations were determined. 




The significance of the area under the curve and the coordinate points of the ROC curves 
are included in Appendix F 
Figure 1. ROC Curve. Serum 
creatinine before surgery 
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Figure 2. ROC Curve. Serum 
cystatin C before surgery 
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From the coordinate points the following data was extracted: 
Creatinine >= 111 
>= 120.5 
>=99 














Table III. Sensitivity and specificity data for baseline serum creatinine in u.mol/1 and 
serum cystatin C in mg/1 in diagnosing a calculated GFR < 72 ml/min 
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4.2 RENAL FAILURE DIAGNOSIS 
4.2.2 Does an overall 37% increase in serum cystatin C diagnose more patients with 
renal dysfunction than an overall 25% or 44 umol/1 increase in serum creatinine? 
INTRODUCTION 
We set out to determine if cystatin C was a better test than serum creatinine in detecting 
patients with renal failure. The definition of a significant rise in creatinine varies in the 
literature (Section 2.2). The biological variability is 15%. We used an increase of more 
than 25% as denoting a significant rise in serum creatinine. Other papers have used 
definitions of a greater than 44 umol/1 or 88 umol/1 rise in serum creatinine. We have 
used a cut-off point as a rise greater than 44 umol/1. From the reports on cystatin C, the 
biological variation is known to be 37% (Section 2.3). Increases more than 37% are 
considered significant. 
METHODS 
Values for baseline (Tl) were compared to the subsequent six time points (T2 - T7) to 
calculate the number of patients with a positive diagnosis using the definitions of renal 
dysfunction explained above. McNemar's Chi Squared Test for related samples was used 
to determine if the overall proportions of positive results with the different diagnostic 
tests were similar. 
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RESULTS 
(For each variable 0 = no, 1 = yes) 
2X2 Table for rise in serum Creatinine > 25% vs rise in Cystatin C > 37% 
Rise in serum creatinine 0 Count 
>25% % within Creatinine 
rise>25% 
% within Cystatin C 
rise> 37%) 
1 Count 
% within Creatinine 
rise>25% 
% within Cystatin C 
rise> 37%) 
Total Count 
% within Creatinine 
rise>25% 
% within Cystatin C 
rise> 37%) 








































a- Binomial distribution used. 
There is no significant difference between the proportions of positive diagnoses using the 
outcomes of a rise in serum creatinine >25% vs. a rise in serum cystatin C >37%. 
46 
2X2 Table for rise in serum Creatinine > 44 micromol/l vs rise in Cystatin C > 37% 
Rise in serum creatinine 0 Count 
>44 micromol/l »/„ wjthin Creatinine rise 
>44mmol 
% within Cystatin C rise > 
37% 
1 Count 
% within Creatinine rise 
>44mmol 
% within Cystatin C rise > 
37% 
Total Count 
% within Creatinine rise 
>44mmol 
% within Cystatin C rise > 
37% 








































a Binomial distribution used. 
There is no significant difference between the proportions of positive diagnoses using the 
outcomes of a rise in serum creatinine > 44 umol/1 vs. a rise in serum cystatin C >37%. 
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4.2 RENAL FAILURE DIAGNOSIS 
4.2.3 Does a 37% increase in serum Cystatin C diagnose patients with renal 
dysfunction earlier than a 25% or 44 u.mol/1 increase in serum creatinine? 
INTRODUCTION 
We set out to assess if a rise in serum cystatin C diagnosed more patients than a rise 
serum creatinine at each time point (T2 - T7). This is similar to the analysis in 4.2.2 but 
involves comparing the proportions of positive diagnoses at each individual time point 
rather that overall. This was done to see if a rise in serum cystatin C occurred earlier than 
a rise in serum creatinine for each individual patient. 
METHODS 
Values for baseline (Tl) were compared to each of the subsequent six time points (T2 -
T7) to calculate the number of patients with a positive diagnosis using the definitions of 
renal dysfunction explained above. McNemar's Chi Squared Test for related samples was 
used for each time point, to determine if the proportions of positive results with the 
different diagnostic tests were similar. 
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The data is presented first for: 
A) a rise in creatinine > 25% versus a rise of serum cystatin C>37% 
Each 2x2 table represents the proportions for each time point: T2, T3, T4, T5, 
T6, T7. 
B) a rise in creatinine > 44 famol/l versus a rise of serum cystatin C>37% 




A) A rise in serum creatinine > 25% verses a rise of serum cystatin C > 37%. 
(For each variable 0 = no, 1 = yes) 
2x2 Table for a rise in serum Creatinine > 25% vs a rise in 
Cystatin c > 37% (T2) 
Count 
Rise in serum 0 
creatinine > 25% 
Total 
Rise in serum cystatin 




















2x2 Table for a rise in serum Creatinine > 25% vs a rise in 
Cystatin c > 37% (T3) 
Count 
Rise in serum 0 
creatinine > 25% 
Total 
Rise in serum cystatin 




















2x2 Table for a rise in serum Creatinine > 25% vs a rise in 
Cystatin c > 37% (T4) 
Count 
Rise in serum 0 
creatinine > 25% 
Total 
Rise in serum cystatin 










For time points T2, T3 and T4 there were no patients diagnosed with renal dysfunction 
using rise in serum creatinine > 25%, despite positive results using a rise of serum 
cystatin C > 37%. 
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2x2 Table for a rise in serum Creatinine > 25% vs a rise in Cystatin c > 37% (T5) 
Rise in serum creatinine 0 Count 
> 25% % within SCR525YE 
% within T537%riseCys 
1 Count 
% within SCR525YE 
% within T537%riseCys 
Total Count 
% within SCR525YE 
% within T537%riseCys 
Rise in serum cystatin 







































a- Binomial distribution used. 
2x2 Table for a rise in serum Creatinine > 25% vs a rise in Cystatin c > 37% (T6) 
Rise in serum creatinine 0 Count 
> 2 5 % % within SCR625YE 
% within T637%riseCys 
1 Count 
% within SCR625YE 
% within T637%riseCys 
Total Count 
% within SCR625YE 
% within T637%riseCys 
Rise in serum cystatin 







































a- Binomial distribution used. 
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2x2 Table for a rise in serum Creatinine > 25% vs a rise in Cystatin c > 37% (T7) 
Rise in serum creatinine 0 Count 
> 25% % within SCR725YE 
% within T737%riseCys 
1 Count 
% within SCR725YE 
% within T737%riseCys 
Total Count 
% within SCR725YE 
% within T737%riseCys 
Rise in serum cystatin 







































a- Binomial distribution used. 
For time points T5, T6 and T7 there was no statistical difference between the proportions 
of patients diagnosed with renal dysfunction using a rise in serum creatinine > 25% or 
using a rise of serum cystatin C > 37%. 
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B) A rise in serum creatinine > 44 u.mol/1 verses a rise of serum cystatin C > 37%. 
(For each variable 0 = no, 1 = yes) 
2x2 Table for a rise in serum Creatinine > 44 micromol/l vs a rise in 
Cystatin c > 37% (T2) 
Count 
Rise in serum creatinine 0 
> 44 micromol/l 
Total 
Rise in serum cystatin 














2x2 Table for a rise in serum Creatinine > 44 micromol/l vs a rise in 
Cystatin c > 37% (T3) 
Count 
Rise in serum creatinine 0 
> 44 micromol/l 
Total 
Rise in serum cystatin 










2x2 Table for a rise in serum Creatinine > 44 micromol/l vs a rise in 
Cystatin c > 37% (T4) 
Count 
Rise in serum creatinine 0 
> 44 micromol/l 
Total 
Rise in serum cystatin 










For time points T2, T3 and T4 there were no patients diagnosed with renal dysfunction 
using rise in serum creatinine > 44 umol/1, despite positive results using a rise of serum 
cystatin C > 37%. 
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2x2 Table for a rise in serum Creatinine > 44 micromol/l vs a rise in Cystatin c > 37% (T5) 
Rise in serum creatinine 0 Count 
> 44 micromol/l % within T544riseCr 
% within T537%riseCys 
1 Count 
% within T544riseCr 
% within T537%riseCys 
Total Count 
% within T544riseCr 
% within T537%riseCys 
Rise in serum cystatin 







































a- Binomial distribution used. 
2x2 Table for a rise in serum Creatinine > 44 micromol/l vs a rise in Cystatin c > 37% (T6) 
Rise in serum creatinine 0 Count 
> 44 micromol/l % within T644riseCr 
% within T637%riseCys 
1 Count 
% within T644riseCr 
% within T637%riseCys 
Total Count 
% within T644riseCr 
% within T637%riseCys 
Rise in serum cystatin 







































a- Binomial distribution used. 
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2x2 Table for a rise in serum Creatinine > 44 micromol/l vs a rise in Cystatin c > 37% (T7) 
Rise in serum creatinine 0 Count 
> 44 micromol/l % within T744riseCr 
% within T737%riseCys 
1 Count 
% within T744riseCr 
% within T737%riseCys 
Total Count 
% within T744riseCr 
% within T737%riseCys 
Rise in serum cystatin 







































a- Binomial distribution used. 
For time points T5, T6 and T7 there was no statistical difference between the proportions 
of patients diagnosed with renal dysfunction using a rise in serum creatinine > 25% or 
using a rise of serum cystatin C > 37%. 
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DISCUSSION 
The last three subsections have compared serum creatinine with serum cystatin C as tools 
for diagnosing renal failure. 
Cystatin C at the upper reference limit of 0.98 mg/1 had a higher sensitivity (76.9%) than 
creatinine at 111 umol/1 (46.2%) or at 120.5 umol/1 (26.9%) in diagnosing pre-existing 
renal dysfunction (Table III). This is in keeping with the literature. To achieve a similar 
sensitivity with creatinine one would need to use a cut-off value of 99 umol/1, which is 
well within the reference range for serum creatinine. The more conservative upper limit 
of cystatin C of 1.25 mg/1 reveals a sensitivity of 38.5% (not dissimilar to creatinine 
between 111 - 120.5 umol/1). 
Cystatin C appears to be a better marker for detecting baseline renal dysfunction. 
Temporal changes (rise) in serum creatinine and cystatin C were then examined. In 
section 4.2.2 the overall proportions of diagnoses of renal failure was no different with 
cystatin C or creatinine at either the 25% or 44 umol/1 cut-off level. 
When examined at each time point, a cystatin C rise > 37% appeared to be better at 
detecting changes at pre-aortic cross-clamp (T2) and prior to lower limb reperfusion (T3). 
No statistical significance could be determined, as the two cut-off points for creatinine 
did not pick up any positives. 
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The biological variability of cystatin C (37%) is far greater than creatinine (15%). One 
would expect that creatinine would be more sensitive in detecting (temporal) changes 
within an individual patient based on the variability. A smaller rise in creatinine is 
necessary to be considered significant. Other definitions of renal dysfunction e.g. 
creatinine rise > 88 u.mol/1 or a doubling of serum creatinine would be expected to yield 
even lower sensitivities. 
Cystatin C is a better marker for diagnosing pre-existing renal dysfunction in a population 
and furthermore appears to be sensitive in picking up changes in renal function over time. 
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4.3 EARLIER MARKERS OF RENAL DYSFUNCTION 
INTRODUCTION 
The last section investigated changes in the assays based on biological variability. A 
comparison of the number of positive diagnoses at each individual time point was done to 
determine which assay yielded a higher proportion of positive diagnoses. We examined 
for the earliest time point that showed a difference and sought the assay responsible. 
Here we examined the mean values of data at each time point (T2 - T7) to see which 
assays demonstrated a statistically significant rise compared to the baseline (Tl). We then 
examined for the earliest time point that showed a statistical difference and sought the 
assays responsible. 
The aim was to determine the value of the alternative assays to serum creatinine as earlier 
markers of renal damage in patients undergoing aortic surgery. 
METHODS 
Analysis revealed the data was not normally distributed and hence a logarithmic 
transformation of all the data for the four assays at the seven time points was done. 
Thereafter plots for each of the four assays were constructed for the mean natural log 
value at each time point. 
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Repeated measures ANOVA was then performed using a simple contrast of each time 
point versus the baseline value (Tl). Univariate tests of the overall within-subjects effects 
of time were analysed (Lower-bound). The specific within-subjects contrast for each of 
the time points (T2 - T6) versus the baseline (Tl) was then analysed to detect the first 
time point (Tx) at which there was a significant rise in mean value. This was done in turn 
for each of the 4 assays. 
Comparison was then made between the Tx values of the 4 assays to determine which 



























Figure 3. Change in mean log serum creatinine at 7 sample points in 







Figure 4. Change in mean log serum cystatin C at 7 sample points in 
patients undergoing aortic surgery. Error bars are 95% CI 
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Creatinine: The effect of time overall on mean serum creatinine was significant (Lower-
bound F = 10.136, P = 0.004). 
For the specific time points, there was a significant difference in mean serum creatinine at 
T2 (P = 0.006) and T3 (P = 0.01) versus the baseline (T10. This was not clinically 
significant as the mean creatinine values are lower than Tl (Figure 3). The first 
significant rise in mean creatinine occurs at T5 (F = 13.091, P = 0.001). 
Cystatin C: The effect of time overall on mean serum cystatin C was significant (Lower-
bound F = 10.944, P = 0.003). 
For the specific time points, the first significant change in mean Cystatin C occurred with 

















Figure 5. Change in mean log urine albumin:creatinine at 7 sample 









Figure 6. Change in mean log urine aGST:creatinine at 7 sample 
points in patients undergoing aortic surgery. Error bars are 95% CI 
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Urine albumin:creatinine: The effect of time overall on mean urine albumin xreatinine 
was significant (Lower-bound F = 26.870, P = 0.000). 
For the specific time points, at T2 there was a significant rise in mean urine 
albuminxreatinine (F = 27.693, P = 0.00) (Figure 5). 
Urine aGSTrcreatinine: The effect of time overall on mean serum aGSTxreatinine was 
significant (Lower-bound F = 15.977, P = 0.001) 
For the specific time points, at T2 there was a significant rise in urine aGSTxreatinine (F 
= 31.345, P = 0.00) (Figure 6). 
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DISCUSSION 
Serum creatinine, a measure of glomerular filtration rate (GFR) appears to decrease 
during the intra-operative period. The other marker of GFR, cystatin C, does not follow 
this pattern. Creatinine levels may fall in cases of decreased muscle mass or protein 
intake but these are long-term effects (see Section 2.2). Tubular secretion of creatinine 
may be affected by drugs and reabsorption of creatinine may occur in states of low urine 
flow rate. In any event, both of these mechanisms would result in increased levels of 
serum creatinine. Increased tubular secretion of creatinine is possible but increased 
recovery of urinary a-GST suggests tubular cell damage. If the drop in serum creatinine 
is reflective of an improvement in GFR then it is difficult to explain the absence of a 
similar drop in cystatin C. 
Both markers first rise significantly only on Day-1 post operation. Cystatin C is therefore 
no better than serum creatinine in detecting early renal dysfunction, specifically a fall in 
the GFR. Furthermore, these findings suggest that GFR only significantly deteriorates on 
the first post-operative day but that the deterioration begins immediately after lower limb 
reperfusion (T4). Factors implicated in reperfusion injury may be implicated in the onset 
of deterioration of GFR. Intensive intra-operative anaesthetic management is evidenced 
by the maintenance of high urine flow rates (Table II). This may further delay the onset 
of deterioration in GFR. 
Both urine albuminxreatinine and urine alpha GSTxreatinine show an almost immediate 
significant rise prior to aortic cross-clamp (T2) and remain elevated until the first post-
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operative day. Changes in glomerular permeability and proximal tubular cellular damage 
start to occur on induction of anaesthesia, despite maintenance of high urinary flow rates. 
All patients were given a dose of vancomycin on induction of anaesthesia and this has 
been implicated in renal damage. 
Furthermore inhalational anaesthetic agents have also been shown to affect the kidneys. 
Desflurane has been investigated and found to have no effect on the recovery of aGST in 
the urine, unlike Sevoflurane. Low-flow isoflurane show similar results to desflurane. 
The present population was exposed to high-flow desflurane and isoflurane (A 
comparison of the median peak assay values stratified by inhalational anaesthetic agent is 
discussed in Section 4.5) 
The question that may be posed here is whether the degree of significant rise in the 
urinary markers albumin and aGST at T2 is predictive of eventual renal dysfunction. 
ROC Curve analysis of the T2 values for urine albumin xreatinine and urine alpha 
GSTxreatinine as predictors for dialysis are discussed in Section 4.5 and the tables and 
figures can be found in Appendix I. 
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4.4 INFRA-RENAL VERSUS SUPRA-RENAL CROSS-CLAMP 
INTRODUCTION 
In the previous 2 sections an analysis was performed on the entire group of patients 
undergoing aortic surgery (n=35) looking at the value of the different assays as earlier 
markers of renal damage. In this section we analyse the group of patients by whether or 
not a supra-renal (SR) or infra-renal cross clamp (IR) was applied. 
Previous analysis (Table 4.2) showed only 'renal' dopamine and the presence of 
ischaemic heart disease to be significantly different variables between the 2 groups. 
'Renal' dopamine was infused in all SR group and just over half of IR group. Neither 
'renal' dopamine nor the presence of ischaemic heart disease was positively or negatively 
related to the outcome of dialysis dependence (see Results section 4.5). We have 
therefore assumed, for interpretation of the results for this section, the difference between 
the 2 groups is primarily the period of true renal ischaemic time, resultant from the 
application of the supra-renal cross clamp (median 20 minutes). 
We wished to assess the mechanism of injury to the nephron induced by true ischaemia. 
METHODS 
Analysis revealed that the data was not normally distributed and therefore a logarithmic 
transformation of all the data for the four assays at the seven time points was done. 
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Thereafter plots for the four assays were constructed using the means of the natural log 
value at each time point, by supra- or infra-renal cross clamp. 
T-Test: Initially T-Tests were performed to determine if there was any significant 
difference at Tl (baseline) between the supra-renal (SR) group and infra-renal (IR) group 
mean log values for each assay. This was done to test for any possible bias between the 
two groups in terms of pre-existing renal dysfunction as measured by each of the four 
assays. 
Similar analyses at the next six time points were also performed. 
ANOVA: Repeated measures ANOVA were performed on the whole group of patients. 
We used a simple contrast of each time of the six point times (T2 - T7) versus the 
baseline value (Tl), testing for within-subjects and between-subjects effects of the factor 
of a supra-renal aortic cross-clamp. This is similar to the analysis performed in Section 
4.4 but with the addition of the factor SR or IR. 
Patients were then stratified into two groups by whether they underwent a supra-renal 
(SR) or infra-renal (IR) aortic cross-clamp. Repeated measures ANOVA was then 
performed separately on each group using a simple contrast of each of the six time points 
(T2 - T7) versus the baseline value (Tl). The specific within-subjects contrast for each of 
the time points (T2 - T7) versus the baseline (Tl) was then analysed to detect the first 
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RESULTS 
T-Test: Analysis for equal variance (Levine's Test) at Tl between SR and IR showed 
only serum albumin to have a significant value (F = 5.156, P = 0.03). For the other 3 
assays equal variance was assumed in applying the t-test for equality of means. 
2-Tailed t-tests showed no significant difference between supra-renal (SR) and infra-renal 
(IR) at baseline (Tl) for all four assays. 
For the subsequent five time points only urine GST showed a significantly higher mean 
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values are lower than Tl (see figure 5). The first significant rise in creatinine occurs at T5 
(F = 13.407, P = 0.001). 
SR: For patients undergoing surgery with a supra-renal aortic cross-clamp (SR) there was 
no significant difference in mean log serum creatinine from the baseline. However, at T5 
(F = 6.625, P = 0.05) and T6 (F = 6.076, P = 0.57) the difference (increment) approaches 
statistical significance. 
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Serum cystatin C 
SR 
IR 
1 2 3 4 5 6 7 
TIME POINTS 
Figure 8. Change in mean serum cystatin C at 7 sample 
points stratified by supra-(SR) or infra-renal (IR) aortic cross-clamp 
The Lower-bound test of the within-subjects interaction of time and supra-renal or infra-
renal clamp was not significant (F = 1.910, P = 0.179). The between-subjects effect of a 
supra-renal or infra-renal clamp was also not significant (F = 0.005, P = 0.946). 
IR: For patients undergoing surgery with an infra-renal (IR) aortic cross-clamp the mean 
log of serum cystatin C was significantly different (elevated) from baseline (Tl) at T5 (F 
= 9.403, P = 0.006). 
SR: For patients undergoing supra-renal aortic cross-clamp (SR) the value at T2 (F = 








be clinically significant. The first significant rise in the assay occurred at T6 (F = 9.143, P 





Figure 9. Change in mean log urine albumin:creatinine at 7 sample 
points stratified by supra- (SR) or infra-renal (IR) aortic cross-clamp 
The Lower-bound test of the within-subjects interaction of time and supra-renal or infra-
renal clamp was not significant (F = 0.750, P = .395). The between-subjects effect of a 
supra-renal or infra-renal clamp was also not significant (F = 0.203, P = 0.656). 
The value at T2 was significantly elevated from baseline in both groups IR (F = 18.927, 
P = 0.000) and SR (F = 21.029, P = 0.019). 
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Figure 10. Change in mean log urine aGSTcreatinine at 7 sample 
points stratified by supra- (SR) or infra-renal (IR) aortic cross-clamp 
The Lower-bound test of the within-subjects interaction of time and supra-renal or infra-
renal clamp was not significant (F = 3.289, P = 0,083). The between-subjects effect of a 
supra-renal or infra-renal clamp was found to be highly significant (F = 35.242, P < 
0.001). 
IR: For patients undergoing an infra-renal aortic cross-clamp (IR) there was a sustained 
significant rise in urine aGST: creatinine at T2, T3 and T4 (F = 28.625, P < 0.001). 
SR: The patients undergoing a supra-renal (SR) aortic cross-clamp showed a statistically 
significant rise in urine aGST: creatinine at T4 (F = 32.550, P = 0.011). 
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DISCUSSION 
There was no difference between supra-renal (SR) and infra-renal (IR) mean values for 
all four assays at the baseline (t-Test). This is not unexpected as there was also no 
significant difference between calculated creatinine clearances at baseline (Table I). 
We can then assume that baseline renal function in both groups SR and IR were similar. 
Subsequent change in renal function measurement is therefore due to any factors 
affecting function during the perioperative period. We have shown that the only 'positive' 
intervention significantly in favour of the group undergoing supra-renal cross-clamp is 
the infusion of Dopamine at 'renal' doses. The only obviously significant negative 
difference is the supra-renal clamp itself. This group was therefore subjected to a period 
of true renal ischaemia of 20 minutes. 
T-test analysis showed that only urinary alpha GST:creatinine was significantly higher in 
the group undergoing supra-renal aortic cross-clamp. This assay is a marker of proximal 
renal tubular cell injury. The markers of GFR (serum creatinine and serum cystatin C) 
and of glomerular permeability (urine albumin) rose with time but there was no 
significant difference between the two groups SR and IR. 
This was similarly shown by the repeated measures ANOVA where the between-subjects 
effects of time and a supra-renal or infra-renal clamp were found only to be significant 
for the assay urinary GSTxreatinine. 
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The nephrotoxic effect of true renal ischaemia appears to be directed at the proximal 
tubular cell rather than at sustained deterioration in GFR or glomerular permeability. The 
S3 segment of the proximal tubule has been shown in the rat model to be the most 
sensitive to ischaemia. Alpha-GST is highly specific for the cells of the proximal tubule 
(Section 2.4). 
However, the multifactorial nature of the renal insults that occur during the perioperative 
period of aortic surgery result in global deterioration in renal function measurements. As 
shown in the previous chapter the urinary assays for albumin and GST are earlier markers 
for deteriorating renal function. Infra-renal aortic cross-clamp is likely to also cause renal 
ischaemia by distortion of the peri-renal aorta and changes in the renal blood flow 
haemodynamics and autoregulation. 
Comparison of values for T2 to T7 versus the baseline for each group SR (n=9) and IR 
(n= 26) is a similar analysis to that of the previous chapter where this was performed for 
the whole group of 35 patients (ANOVA). Similar trends are seen in that elevations in the 
urinary assays appear to be earlier markers of deterioration in renal function versus serum 
creatinine and serum cystatin C. 
The failure to conclusively demonstrate this trend for the supra-renal group is probably a 
type II error. The limitations of small numbers of patients with a supra-renal clamp were 
further exacerbated by the listwise exclusion of patients with missing values, when 
performing the statistical analysis (SPSS 11.0 for Windows). The large variance in 
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measured values also contributed to the inability to demonstrate any significant change 
though the graphical representations in figures 7-10 suggest similar trends to those in the 
IR group. 
The significant drop in Cystatin C at T3 in the supra-renal group when compared to the 
infra-renal group (figure 8) might be explained by the use of'renal' dopamine in all these 
patients and the slightly higher urine flow rates that were achieved (Table II). The other 
marker of GFR, serum creatinine, demonstrates a similar trend. (Figure 7). 
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4.5 RENAL FAILURE PREDICTION 
INTRODUCTION 
An ability to predict post-operative renal dysfunction is useful not only for purposes of 
prognosis but also for deciding on strategies to minimise renal dysfunction. We defined 
renal dysfunction as either one of four outcomes (Section 4.2): 
o Dialysis dependence 
o Overall rise in serum creatinine > 37% 
o Overall rise in serum creatinine > 44 u.mol/1 
o Overall rise in serum cystatin C > 37% 
The predictors used were: 
o Baseline serum creatinine > 120 fimol/1 
o Baseline serum cystatin C > 1.24 mg/1 
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METHODS 
A) In order to exclude bias we initially investigated for an association between the 
variables shown in Table 4.1 (pre-operative) and Table 4.2 (intra-operative) and the hard 
outcome of dialysis dependence 
o Sex, Age, Supra- or Infra-renal aortic cross-clamp 
o Diabetes, Hypertension, Hyperlipidaemia, Smoking, ACE inhibitor drugs, 
History of ischaemic heart disease and History of stroke 
o Anaesthetic agent, Mannitol, 'Renal' Dopamine, Frusemide, Hypotension 
and Inotrope 
o Blood loss, Units packed cells transfused, Intraoperative urine flow, 
Anaesthetic time, Surgery time and Lower limb ischaemic time 
Fisher's Exact Test was performed on all the nominal variables from Tables I and II and 
Mann-Whitney Test on the continuous variables to determine if there was any difference 
between those patients that eventually needed dialysis and those that did not. 
Furthermore, as suggested in Section 4.3, we also investigated the outcome of peak urine 
albumin: creatinine and aGSTxreatinine (continuous variables) to see if there was a 
significant difference in the median values in the group who had isoflurane and those 
who had desflurane as an inhalational anaesthetic agent (Mann-Whitney test) 
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B) We used the previously defined predictors of renal dysfunction to stratify patients: 
o Baseline serum creatinine > 120 umol/l 
o Baseline serum cystatin C > 1.24 mg/1 
The sensitivity and specificity for diagnosing renal failure by each of the 4 outcomes was 
calculated after the construction of 2 x 2 Tables. 
C) Receiver operating characteristic (ROC) curves were then calculated for the outcome 
'dialysis' and the continuous baseline variables 
o Serum creatinine 
o Calculated creatinine clearance 
o Serum cystatin C 
o Urine albuminxreatinine 
As suggested in Section 4.3 ROC Curves were also plotted for the T2-values (rather than 
baseline) of urine albuminxreatinine and aGSTxreatinine using 'dialysis' as an 
outcome. We showed earlier that the urinary markers rose significantly at T2 and here we 
have looked at whether there was an association between this and dialysis i.e. could the 




Outcome Dialysis: For each of the variables described under Method A there was no 
significant difference between those patients that required dialysis and those that did not. 
'Anaesthetic agent' and Peak urinary markers: Median peak urine albuminxreatinine 
was higher (but not significantly) in the isoflurane group (220.24 mg/mmol) versus the 
desflurane group (86.34 mg/mmol) (P = 0.077). 
Median peak urine aGSTxreatinine was higher (but not significantly) in the isoflurane 
group (31.97 u.g/mmol) versus the desflurane group (6.00 u.g/mmol) (P = 0.271) 
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B) Sensitivities and specificities. (2x2 Tables are included in Appendix G.) 
Baseline creatinine > 120 umol/l 




Positive predictive value 
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72.2 - 97.5 
35.9-91.8 
52.9-84.7 
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Baseline cystatin C > 1.24 mg/l 
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95% Confidence Interval 
17.7-64.5 
56.6 - 89.9 
23.7 - 76.3 
48.4-82.8 
Baseline serum cystatin C > 1.24 mg/l * outcome Dialysis 
Sensitivity 
Specificity 
Positive predictive value 






95% Confidence Interval 
37.6 - 96.4 
62.7 - 90.5 
16.8-68.7 
80.5 - 99.3 
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C) ROC Curves for continuous baseline variables and outcome 'dialysis' 
(significance of the area under the curve and coordinates of the curve are included in 
Appendix H) 
Figure 11. ROC Curve. Baseline 
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A calculated creatinine clearance <= 48.5 ml/min has a 100% sensitivity and 
73.3%specificity for predicting dialysis. Using a cut-off <= 43.7 ml/min yields values of 
80% and 83.3% respectively. 
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Figure 12. ROC Curve. Serum 
creatinine before surgery 
Outcome dialysis 
1.00 
0.00 .25 .50 
1 - Specificity 
1.00 
A cut-off serum creatinine >= 117.5 u.mol/1 improves the sensitivity from 60% (120 
u.mol/1) to 80% in predicting dialysis. 
Figure 13. ROC Curve. Serum 
cystatin C before surgery 
Outcome dialysis 
1.00 
0.00 .25 .50 .75 1.00 
1 - Specificity 
Diagonal segments are produced by ties. 
Using a cut-off of serum cystatin C >= 1.34 yields an unchanged sensitivity of 80% and 
an improved specificity of 86.7% for predicting dialysis. 
85 
Figure 14. ROC Curve. Urine 
albumin:creatinine before surgery 
Outcome dialysis 
1 - Specificity 
The area under the curve is not significantly different from 0.5. However, an estimate of 
the sensitivity and specificity for a value >= 3.97 mg/mmol is 80% and 55.5% 
respectively. 
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Continuous T2 variables for urinary albumin:creatinine and urinary 
aGSTrcreatinine and outcome 'dialysis'. 
The area under the curve for both variables was not significantly different from 0.5. 
The significance test results and ROC curves are included in Appendix I. 
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DISCUSSION 
A) Although the median peak urinary assay values were not significantly different in 
those who had isoflurane anaesthesia, there was a trend towards higher means. Past 
studies have shown no significant rise in urinary aGST after desflurane and low-dose 
isoflurane anaesthesia. All patients in the present study had high-flow desflurane or 
isoflurane. It is possible that there exists a dose-related response of urinary markers to 
isoflurane. Further studies may help. 
B) The sensitivity of baseline serum creatinine > 120 u.mol/1 and serum cystatin C > 1.24 
mg/1 in predicting renal dysfunction defined by biochemical changes is poor. Serum 
creatinine > 120 urnol/l appears to have overall better specificity. 
For the hard outcome of 'dialysis' cystatin C has better sensitivity (80%) and specificity 
(80.8%) than creatinine. The low positive predictive values are in part due to the low 
prevalence of'dialysis', which occurred in only 5 patients. The large confidence intervals 
may be explained by the small sample size. 
C) The ROC curves for the baseline values show that similar sensitivities (80%) and 
specificities (83.3 - 86.7%) can be obtained for creatinine clearance, serum creatinine and 
serum cystatin C by manipulating the cut-off points. The change in cut-off in serum 
creatinine from 120u.mol/l to 117.5 u.mol/1 and in serum cystatin C from 1.24 mg/1 to 
1.34 mg/1 is within the biological variability of each assay and therefore may not be 
clinically relevant. 
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Using T2 urine albuminxreatinine does not yield improved sensitivities and specificities 
for predicting dialysis when compared to baseline ratios. 
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CHAPTER 5 RESULTS FOR PATIENTS UNDERGOING 
EXPOSURE TO INTRAVASCULAR CONTRAST 
5.1 PATIENT DEMOGRAPHIC DATA 
Thirty-seven patients underwent exposure to an intravenous contrast load (Table IV). The 
median age was 72.8 years and the median Cockcroft-Gault calculated creatinine 
clearance at baseline was 53.4 ml/min. Iohexol was used for all the patients and the 






Calculated baseline creatinine 




Ischaemic Heart Disease 
Stroke 
ACE inhibitor drugs 
Total 



























Table IV. Data for patients undergoing exposure to intravascular contrast (n=37). 11 
patients subsequently underwent surgery. Continuous variables are median. 
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There was only 1 patient that had a serum creatinine rise > 25% or > 44 u.mol/1. 3 patients 
developed a rise in cystatin C > 37%. There was no association between the volume of 
contrast used and the development of these outcomes. 
Eleven patients subsequently underwent aortic surgery (C+S). There was no significant 
difference in any of the variables for these 11 patients versus the whole group of 37 
patients (Fisher's Exact test for nominal data and Mann-Whitney test for continuous 
data). This group is discussed further in Chapter 6. 
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5.2 EARLIER MARKERS OF RENAL DYSFUNCTION 
INTRODUCTION 
Statistical analysis of the mean values of the four assays from time point 1 (CI) to time 
point 3 (C3) was performed. Results for time points 2 and 3 were compared in turn with 
the result for time point 1. We then examined for the earliest time point that showed a 
significant rise compared to baseline. 
The aim was to determine the value of the alternative assays to serum creatinine as earlier 
markers of renal damage in patients undergoing intravascular contrast exposure. (This 
methodology is similar to that of Section 4.3) 
METHODS 
Initial analysis showed the data was not normally distributed. Logarithmic transformation 
of the values of the four assays at each of the three time points was performed. Plots for 
the four assays were constructed using the means of the natural log value at each time 
point. 
Repeated measures ANOVA was performed using a simple contrast of each of the two 
time points (C2 and C3) versus the baseline (CI). Univariate tests of the overall within-
subjects effects of time were analysed (Lower bound). The specific within-subjects 
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contrast for each of the two time points versus the baseline was then analysed to detect 
the first time (Cx) point at which there was a significant rise in each of the four assays. 
Comparison was then made between the Cx values of the 4 assays to determine which 




Figure 15. Change in mean log serum creatinine at 3 sample points in 
patients undergoing contrast exposure. Error bars are 95% CI 
TIME POINTS 
Figure 16. Change in mean log serum cystatin C at 3 sample points in 
patients undergoing contrast exposure. Error bars are 95% CI 
94 
Serum creatinine: The effect of time overall on mean serum creatinine was not 
significant (Lower-bound F = 0.872, P = 0.361). 
For the specific time points there was no significant change in serum creatinine. 
Cystatin C: The effect of time overall on mean serum cystatin C was not significant 
(Lower-bound F = 0.047, P = 0.830). 
For the specific time points there was no significant change in serum cystatin C. 
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Figure 17. Change in mean urine albumin:creatinine at 3 sample points in 






















Figure 18. Change in mean log urine aGST:creatinine at 3 sample points 
in patients undergoing exposure to contrast. Error bars are 95% CI 
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Urine albumin:creatinine: The effect of time overall on mean urine albuminxreatinine 
was not significant (Lower-bound F = 1.927, P = 0.181). 
For the specific time points, there was a significant difference in mean urine 
albuminxreatinine at C3 versus baseline (CI) (F = 5.537, P — 0.030) but examination of 
Figure 11 shows this to be lower than baseline. 
Urine aGST:creatinine: The effect of time overall on mean urine serum 
aGSTxreatinine was significant (Lower-bound F = 6.074, P = 0.024). 




The use of Iohexol, a low-osmolar non-ionic agent, and the low incidence of diabetes in 
this population may explain the minimal morbidity seen after contrast exposure. From the 
literature one would have expected a renal failure incidence of 12% (4.4 patients) using a 
definition of creatinine rise > 44umol/l for patients with renal impairment (Section 1.2.3). 
The use of an intravenous saline infusion to maintain intravascular volume and promote 
diuresis may have affected the rate of renal impairment but the small sample size again, 
may be misleading. For purposes of the above analysis, no attempt was made to 
investigate for predictors of renal dysfunction, and hence the possible bias of the effect of 
a saline infusion is not entered into. 
Urine GSTxreatinine appears to be a more sensitive marker for renal injury after 
intravascular contrast exposure than the other three assays. Contrast therefore has toxic 
effects on the proximal tubular cell. 
Unlike the data for patients undergoing surgery, the two urinary assays do not mirror each 
other. Urine albumin xreatinine drops significantly after contrast exposure while 
GSTxreatinine rises significantly. Increased recovery of urine albumin can be due to 
increase glomerular permeability or decreased tubular absorption. It is unlikely that 
tubular absorption of albumin is enhanced by the exposure to contrast; in fact the 
significant rise in GSTxreatinine suggests otherwise. Exposure may therefore result in 
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proximal tubular cell injury while its effect on the glomerulus is that of decreased 
permeability. This has not been described before. Glomerular filtration rate appears not to 
be affected. 
Despite graphic representations suggesting the mean log of cystatin C continues to rise 
while that of creatinine drops at C3, the mean of the absolute cystatin c value at C3 
(1.380 mg/1) is similar to the baseline Tl (1.378 mg/1) (figure 16). The mean of the 
absolute serum creatinine rose from 129.9 u,mol/l (CI) to 134 u.mol/1 (C2). Intravascular 
contrast did not seem to have a significant deleterious effect on GFR in this study. In fact 
reports of a transient rise in renal blood flow are reported. 
Further selective studies using urinary proteins of different molecular weight may help to 
elucidate the effects of contrast on glomerular function. 
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CHAPTER 6 RESULTS FOR PATIENTS UNDERGOING 
EXPOSURE TO INTRAVASCULAR CONTRAST AND 
SUBSEQUENT AORTIC SURGERY 
6.1 COMPARISON OF OUTCOMES AFTER INTRAVASCULAR CONTRAST 
EXPOSURE AND SUBSEQUENT AORTIC SURGERY 
INTRODUCTION 
Many patients undergo preoperative radiological investigations necessitating the 
exposure to intravascular contrast. Contrast may precipitate renal failure but the risk with 
the newer low-osmolar isotonic agents is lower. Nephrotoxicity occurring after contrast 
exposure may be a marker for post-operative renal dysfunction. We investigated this 
possibility using serum creatinine as well as alternative markers of renal injury. 
METHODS 
Eleven patients underwent intravascular contrast exposure (CE) and subsequent aortic 
surgery (S) 
Scatter plots were performed for data obtained after contrast exposure and after initiation 
of surgery. The following variables were used 
o Peak serum creatinine (CE) vs. (S) 
o Peak percentage rise in serum creatinine (CE) vs. (S) 
100 
o Peak serum cystatin C (CE) vs. (S) 
o Peak percentage rise in serum cystatin C (CE) vs. (S) 
o Peak urine aGST: creatinine (CE) vs. (S) 
o Peak percentage rise in aGSTxreatinine (CE) vs. (S) 
In addition, for all three assays Day-1 values after contrast exposure (CE) were compared 
respectively to the peak absolute and peak percentage rise after surgery (S). 
o Creatinine Day-1 (CE) vs. Peak (S) 
o Percentage rise creatinine Day-1 (CE) vs. Peak (S) 
o Cystatin C Day-1 (CE) vs. Peak (S) 
o Percentage rise cystatin C Day-1 vs. Peak (S) 
o a-GST Day-1 (CE) vs. Peak (S) 
o Percentage rise a-GST Day-1 (CE) vs. Peak (S) 
Urine albuminxreatinine levels were shown in section 5.2 not to rise significantly after 
contrast exposure and hence were not used in this analysis. 
A) Data was screened for outliers and then evidence of a linear relationship was sought. 
Non-parametric correlation using Spearman's rho was calculated. 
B) For the variables that showed a linear relationship with significant correlation, the 
interpretation is that as the variable increases post contrast exposure, so too will it 
increase after undergoing surgery. Linear regression was used to estimate the coefficients 
of the linear equation y = bx + a. For the appropriate variable, the regression estimate of y 
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(the value resultant from undergoing surgery) can be obtained from the known value of x 
(value resultant from exposure to contrast). 
The linear regression equation allows estimation of the second value post operation (S) 
based on the value post contrast exposure (CE). 
C) For variables that showed a linear relationship, we investigated the relationship 
between the values after undergoing surgery and the outcome of dialysis (Mann-Whitney 
Test). The whole group of patients undergoing surgery was analysed (n = 35, Section 
4.1). Only 1 patient had a positive outcome of dialysis in the subgroup of 11 patients and 
therefore use of this subgroup was unsuitable for statistical analysis. 
Receiver operating characteristic (ROC) curves of the values were then plotted to 
determine the sensitivity and specificity at different cut-off points in predicting renal 
failure. 
This would determine if there was any clinical significance attached to the statistical 
significance i.e. not only would it be useful to know that a value after contrast can help 
estimate the value after surgery, but if the latter value is associated with a negative 
outcome (e.g. dialysis), then knowing the value of a variable after exposure to contrast 
may help to predict the likelihood of needing dialysis after surgery. 
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RESULTS 
Linear relationships were found between values after contrast (CE) and after surgery (S) 
for the following variables 
• Peak serum creatinine after contrast and after surgery 
• Day-1 serum creatinine after contrast and peak serum creatinine after surgery 
• Peak serum cystatin C after contrast and after surgery 
• Day-1 serum cystatin C after contrast and peak serum cystatin C after surgery 
Urine aGSTxreatinine showed no association between the two groups (neither peak/peak 
% rise nor Day-1/ Day-1 % rise). All correlation coefficients were less than 0.3. 
Exclusion of Patient 3, who was found to be an outlier, did not significantly improve the 
correlation. No further analysis was performed on this subgroup. 
Inspection revealed Patient 1 to be an outlier for both serum creatinine and serum cystatin 
C measurement. The paired data were excluded from the correlation and regression 
analysis. 
The results are presented first for: 
serum creatinine and 




Figure 19. Scatter Plot and regression 
line for serum creatinine 
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Correlation is significant at the 0.01 level (2-tailed). 
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Figure 20. Scatter plot and regression 
line for serum creatinine 
g Day-1 post contrast vs peak surgery 
o 
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Correlation is significant at the 0.01 level (2-tailed). 
Peak serum creatinine after contrast exposure yields a slightly higher correlation 
coefficient with peak serum creatinine after surgery (rho = 0.939), compared to Day-1 



































a. Dependent Variable: Peak serum creatinine after surgery 
The equation for the regression line is therefore 
Y= 1.143 X - 6.093 
Where Y is the estimated peak serum creatinine after surgery 
X is the peak serum creatinine after contrast. 
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C) The Mann-Whitney test showed a significantly higher serum creatinine in patients 
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a. Not corrected for ties. 
b. Grouping Variable: DIALYSIS 
ROC curves were then constructed. 
Figure 21. ROC Curve. Peak 
serum creatinine after surgery 
Outcome Dialysis 
GO 0 .00 
1 - Specificity 
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The area under the curve was significant and a peak serum creatinine >= 162umol/l had a 
sensitivity of 100% and specificity Of 90% (See Appendix J). 
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Serum cystatin C: 
A) 
Figure 22. Scatter plot and regression 
line for serum cystatin C 
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Correlation is significant at the 0.01 level (2-tailed). 
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line for serum cystatin C 
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Correlation is significant at the 0.01 level (2-tailed). 
Day-1 serum cystatin after contrast exposure yields a slightly higher correlation 
coefficient with peak serum cystatin C after surgery (rho = 0.842), compared with peak 
serum cystatin C after contrast exposure (rho = 0.815). Serum cystatin C is not a routine 





































a. Dependent Variable: Peak serum cystatin C after surgery 
The equation for the regression line is therefore 
Y=1.010X + 0.181 
Where Y is the estimated peak serum cystatin C after surgery 
X is the Day-1 serum cystatin C after contrast 
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C) The Mann-Whitney showed a significantly higher serum cystatin C in patients 
requiring dialysis (2.93 mg/1) than those who did not (1.22 mg/1). 
Ranks 
DIALYSIS 
Peak serum 0 
cystatin C 1 















Asymp. Sig. (2-tailed) 










a- Not corrected for ties. 
b. Grouping Variable: DIALYSIS 
ROC curves were constructed. 
Figure 24. ROC Curve. Peak 
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Diagonal segments are produced by ties. 
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The area under the curve was significant and a peak serum cystatin C > 1.67 mg/l had a 
sensitivity of 100% and a specificity of 86.7% in predicting dialysis (see Appendix J). 
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DISCUSSION 
We showed that a significant linear association exists between peak or Day-1 values (CE) 
and the peak value after surgery (S) for both serum creatinine and cystatin C. 
This relationship is important because the values at (S) show a significant association 
with the need for dialysis. It is not unexpected, because the initiation of dialysis is a 
clinical decision based, amongst other factors, on the serum creatinine. We have 
confirmed this statistically using the Mann-Whitney tests. 
Day-1 cystatin C was chosen over peak cystatin C for the linear regression. Unlike 
creatinine, Cystatin C is not routinely performed in all laboratories and this would allow 
for a more repeatable sampling point. 
Serum creatinine and serum cystatin C appear equally useful in predicting post-operative 
assay changes (S) based on the findings after contrast exposure (CE). The coefficients of 
the regression equations are both close to 1 and therefore one can expect a similar 
magnitude of rise after contrast and surgery. 
The confidence intervals for the coefficients of the regression equation are wide. A larger 
sample size may have improved this. 
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SUMMARY 
This study was conducted with the aim of evaluating the role of alternative markers of 
renal dysfunction in vascular surgical patients. 
That renal dysfunction is indeed a significant clinical problem in vascular surgery, has 
been outlined in the earlier chapters of this report. Because of the well-described 
problems associated with the use of serum creatinine as a marker of renal failure, there 
has been a move toward finding better assays to diagnose and predict nephropathy. 
David Newman was involved in much of the work in developing and validating the 
cystatin C assay. Urine a-GST was investigated early on for its use in predicting viability 
of donor kidneys. It has been also used to investigate the toxic effect of certain 
anaesthetic agents on the kidney and more recently in patients undergoing aortic surgery. 
We have shown that cystatin C appears to be a better marker for diagnosing renal 
impairment than serum creatinine. Its apparent improvement over serum creatinine in 
detecting more patients with subsequent deterioration in renal function is unexpected 
given the generous definitions of renal dysfunction using a rise in serum creatinine. 
The surgical insult is initially not associated with deterioration in GFR; in fact serum 
creatinine suggests an improvement in GFR before deterioration on Day-1. Intra-
operative intensive anaesthetic management may explain this phenomenon. The 
115 
cumulative effects of anaesthesia, ischaemia and reperfusion appear to have maximal 
impact on GFR on Day-1. 
The present study clearly demonstrates that urinary markers are more sensitive in 
detecting renal injury. This is true when one compares changes over time. We have also 
shown that true renal ischaemia results in much higher recovery of a-GST in the urine 
compared to infra-renal surgery. This is in keeping with reports of the S3 segment of the 
renal tubule being the most sensitive to ischaemia. 
Intravascular contrast was unimpressive in the induction of renal injury. Aggressive 
medical management and the use of newer contrast agents have decreased the incidence 
of renal dysfunction. The interesting outcome was non-concordance of the GST and 
albumin recovery in the urine. Intense vasoconstriction is described after contrast 
exposure and this leads to hypoxic damage to the nephron. This would explain the 
increased recovery of a-GST in the urine. The concomitant fall in urine albumin is 
unlikely to be due to increased tubular resorption of albumin. Our data suggest that 
glomerular permeability is decreased while the markers of worsening GFR are not 
markedly raised. Further study is needed before firm conclusions can be drawn. 
A clinically important issue is to be able to predict patients that will develop subsequent 
renal dysfunction after intervention. Cystatin C cut-off values are marginally better than 
serum creatinine in predicting renal dysfunction after surgery. 
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It would be expected that there would be a relationship between response to contrast and 
response to surgery. We have shown a strong correlation between the two responses. 
Regression coefficients for both serum creatinine and serum cystatin C were calculated 
but they were both close to unity suggesting that the insult of contrast exposure is similar 
in renal terms to that of surgery. Surgical intervention would be expected to be more 
invasive and should cause a higher peak serum creatinine value. Our data suggest that 
either this is not so or that deterioration in renal function is determined by inherent patient 
factors modified by external factors. However, we were unable to show any difference in 
demographic data and negative outcomes. 
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CONCLUSIONS 
1. Cystatin C is more sensitive than serum creatinine in detecting pre-existing and 
subsequent renal impairment in patients undergoing aortic vascular surgery. 
2. Increased glomerular permeability and proximal renal tubular cell damage almost 
occur immediately after the onset of surgery, whereas significant deterioration 
glomerular filtration rate (GFR) only occurs at day-1 post-operation. 
3. Low-osmolar non-ionic contrast exposure appears to cause proximal tubular cell 
damage without significant deterioration in GFR. Glomerular permeability 
appears to be decreased. 
4. A supra-renal clamp (true renal ischaemia), when compared to an infra-renal 
clamp, appears to cause significantly more proximal tubular cell damage. Similar 
deterioration in GFR and glomerular permeability is seen. 
5. Cystatin C appears to have better sensitivity and specificity for predicting the 
need for dialysis. 
6. After contrast exposure, peak and day-1 serum values of cystatin C and creatinine 
show good correlation with the peak value post aortic surgery. The magnitude of 




This study was conducted primarily to evaluate the value of alternative diagnostic tests 
and hence is littered with statistical methods and calculations. For maximum strength of 
the significance of the positive results a larger sample size would be needed. 
It is likely that this has led to a type II error in some of the calculations i.e. not showing a 
statistically significant difference because of small sample size, when in fact one exists. 
Lastly, interpretation of the results needs to be placed into clinical context. Although 
renal failure is a major problem in patients undergoing vascular surgery, the present study 
has demonstrated biochemical changes that are important in understanding mechanisms 
of renal damage. Not all patients with changes in biochemical markers developed 
clinically overt renal dysfunction. The earlier changes that were observed may well pre-





Creatinine Clearance = 1.23 x (140 - age) x weight / serum creatinine 




KENSINGTON & CHELSEA AND WESTMINSTER HEALTH AUTHORITY 
ST MARY'S LOCAL RESEARCH ETHICS COMMITTEE 
CONSENT FORM 
AGREEMENT TO PARTICIPATE IN RESEARCH PROJECT 
I, (name of subject) 
Of (address) 
Agree to take part (or agree that my child/ward may take part in the research project: 
Risk assessment for renal injury post aortic surgery using new and more 
sensitive markers of renal injury. 
I confirm that the nature and demands of the research have been explained to me and 
I understand and accept them. I understand that my consent is entirely voluntary and 
that 1 may withdraw from the research project if I find that I am unable to continue for 
any reason and this will not affect my medical care. 
Signed: PrintName: 
Witness: Print Name: 
Date: 
Investigator's Statement: 





IMPERIAL COLLEGE SCHOOL OF MEDICAL AT ST MARYS' HOSPITAL 
AGREEMENT FOR THE DONATION OF BLOOD OR TISSUE SAMPLES 
I, (Name of subject) 
of (Address) 
agree to donate any blood or tissue samples taken during the course of my treatment 
under the direction of: 
(Name of consultant): 
and assign all right, title and interest in such samples to ICSM at St Mary's, London W2. 
I confirm that it has been explained to me that the samples may also be used for research 
or teaching purposes and that components of the samples may be used to develop 
commercial diagnostic or therapeutic agents. I understand that, should I not wish my 
samples to be used for these purposes I am free not to sign this form, and that such a 





I have explained to the subject the clinical reasons for taking samples, their possible 
uses, the assignment of ownership and that if the subject did not wish to donate his/her 
samples this would have no effect on his/her clinical care. 
Signed: Date: 
(Name) 
TO BE HELD IN PATIENT'S NOTES OR RETAINED BY THE INVESTIGATOR 
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APPENDIX C 
COPY OF INFORMATION SHEET USED FOR THIS STUDY 
INFORMATION FOR VOLUNTEERS 
Dear Mr./ Mrs./Miss 
Would you consider helping us in our study on kidney failure in patients with 
diseases of the arteries? The following information leaflet explains the details of the 
study. Please contact me should you have any questions. 
Research project title 
Risk assessment for renal injury post aortic surgery using new and more sensitive 
markers of renal injury. 
What is the purpose of the study? 
Ballooning or dilatation of the aorta is called an aortic aneurysm. As the aorta 
enlarges further the risk of the aorta bursting (rupture) is higher. In order to 
avoid this patients are offered an operation to replace the abnormal aorta with a 
man-made tube (prosthetic graft). In patients who have narrowing or blockage 
of the aorta a similar operation is done to increase the blood flow to the legs. In 
order to do this you will undergo X-rays (either a CAT scan or an angiogram) 
and then an operation under general anaesthetic. One of the risks of the 
operation is kidney failure, which occurs partly because the kidneys get their 
blood supply from the aorta near the aneurysm. This risk depends on many 
factors including whether you have kidney problems at the moment and how 
extensive the aneurysm is. The contrast (dye) given to outline the arteries 
during the X-ray may also contribute this. 
We wish to study all the patients who have aortic surgery to see why some 
patients get kidney failure and others do not. We shall do this using new and 
better tests of kidney function. 
In this way we can learn if there are future changes we can make to reduce the 
risk of kidney damage. 
We also plan to study patients that have pain in their legs because of reduced 
blood flow. This is due to narrowed or blocked arteries in their legs and they 
undergo bypass operations in their legs. If this is your problem then the risk of 
kidney failure is much lower but we need to study you as well to compare your 
results with the other patients. You will serve as a comparison with the other 
patients. When doing a study it is a good idea to do this to avoid making false 
conclusions about the results. 
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What will I have to do? 
If you consider helping us we will answer any questions you may have and ask 
you to sign a consent form. Your treatment during your hospital stay will not be 
different to those who choose not to take part in the study. 
The study involves collecting urine and blood samples from you before, during 
and after the operation. This will be done when you have an injection to take 
bloods for other ward test to avoid you any discomfort. 
The results of these tests will be studied to see if we can find out who gets 
kidney failure and why. 
What if I do not want to participate? 
We emphasise that participation in the study is voluntary. The tests do not form 
part of your routine care. You are free to decline. You will remain free to 
withdraw from the study at any stage without any further consequence or 
obligation. This will not affect your care in this hospital. 
What are the risks? 
Research studies may involve some risk, but in this study we do not anticipate 
any. No part of your care will be changed because you are part of the study. 
What are the benefits? 
It is unlikely that this study will benefit you as an individual. However the tests 
will provide information that may benefit patients that need to have the same 
operation in the future. 
How much will it cost? 
The tests are expensive but we will meet the cost. We have applied for a 
research grant. There will be NO additional expense to you. 
What will be done with the results? 
All the information gathered would be strictly confidential. Only the 
investigators will have access to the study information. Once all the information 
is gathered the results of the study will be published in a scientific research 
journals. At no stage will your personal details be given out. 
Who can I contact for further information? 
If you have any questions about this study, you may contact Mr. Pillay (0207 




PATIENT/VOLUNTEER CONSENT CHECKLIST 
The participant or key carer should complete the whole of this sheet himself/herself. 
(please cross out as necessary) 
Have you been asked to consent for yourself or on behalf of someone else? Self/Other 
If your answer to the above is "other" please give the name of the person form 
whom you are consenting: 
Have you read the Information sheet for patients and healthy volunteers? YES / NO 
Have you had an opportunity to ask questions and discuss this study? YES / NO 
Have you received satisfactory answers to all of your questions? YES / NO 
Have you received enough information about the study? YES / NO 
Have you been told whether you would be entitled to reimbursement 
of travel expenses? YES / NO 
Who have you spoken to? Dr / Mrs / Ms / Mr 
Do you understand that your decision to consent is entirely voluntary and that you are free to withdraw 
from the study at any time, without having to give a reason for withdrawing and without affecting your 
future medical care? YES / NO 
Do you agree to take part in this study? YES / NO 
Signed: Date: 
NAME IN BLOCK LETTERS: 
2000/2001 
125 
CONSENT CHECKLIST FOR INVESTIGATORS 
1. Have you given the Patient Information Sheet to the subject? YES / NO 
2. Have you given an oral explanation to the subject, including: 
* this is a research project: YES / NO 
* participation is voluntary: YES / NO 
* the aims of the project: YES / NO 
* the likely duration of the subject's involvement: YES / NO 
* the expected benefits to the subject and/or others: YES / NO 
* the expected nature of the drug or device being tested: YES / NO 
* that the subject may instead, receive a reference treatment or placebo: YES / NO 
* what risks, inconvenience, discomfort of distress may reasonably 
be anticipated for this patient: YES / NO 
* that a refusal to participate may be given without reasons and will not 
affect the care which will be given to the subject: YES / NO 
* that personal information may be scrutinised during audit by competent 
authorities and properly authorised people, but all personal information 
will be treated as strictly confidential and will not be made 
publicly available: YES/NO 
* what compensation arrangements are available: YES / NO 
* whom to contact in an emergency and how: YES / NO 
3. Have you asked the subject: 
• for authorisation to approach his/her GP and for permission for 
• the GP to disclose medical information? YES / NO 
* to tell you if he/she is or has been involved in any other 
research studies: YES / NO 
* to tell you if he/she is or has recently been taking any 
other medication or preparations? YES / NO 
4. If you have answers NO or not answered any of the above 
questions in section 2 or 3, record why: 
5. Have you allowed the subject sufficient time to consider the 
matter on his/her own, discuss with others if wishes, or ask 
you questions? YES / NO 
6. In your opinion, has the subject understood and consented 
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APPENDIX E 



















renal artery stenosis 





renal ischaemia time 




cardio pulmonary bypass 
left heart bypass 
renal perfusion 
left renal patch 
renal jump grafts 
blood loss 
packed cells transfused 
cell saved blood transfused 
peak vancomicin level 
renal support 
peak creatinine 
days in icu 
days in hosp 
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1. preoperation serum creatinine 
serum urea 




2. pre clamp serum creatinine 
serum urea 




3. pre clamp removal serum creatinine 
4.2hrs post clamp removal serum creatinine 
serum urea 









5. day 1 serum creatinine 
serum urea 
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Data for patients undergoing surgery (n= 35). Coordinate points for the ROC Curve 
for baseline serum creatinine and cystatin C * baseline GFR < 72 ml/min 
Area Under the Curve baseline serum creatinine * outcome GFR < 
72ml/min 














The test result variable(s): slcreats has at least one tie between the 
positive actual state group and the negative actual state group. Statistics 
may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
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Coordinates of the Curve baseline serum creatinine 
in micromol/l "outcome GFR < 72 ml/min 
Test Result Variable(s): sicreats 
Positive if 
Greater Than 
































































































The test result variable(s): sicreats has at least one tie 
between the positive actual state group and the negative 
actual state group. 
a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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Area Under the Curve baseline serum cystatin C * outcome GFR < 72 
ml/min 














a- Under the nonparametric assumption 
D Null hypothesis: true area = 0.5 
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Coordinates of the Curve baseline serum creatinine 
in micromol/l * Outcome GFR < 72 ml/min 
Test Result Variable(s): slcystc 
Positive if 
Greater Than 
































































































a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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APPENDIX G 
Data for patients undergoing surgery (n= 35). 2x2 Tables for baseline variables * 
outcomes (For each variable 0 = no, 1 = yes) 
Baseline serum creatinines 20 micromol/l * Creatinine 
rise>25% Crosstabulation 
Count 


















Baseline serum creatinine > 120 micromol/l * serum creatinine 
rise > 44micromol/l Crosstabulation 
Count 
Baseline serum 0 
creatinine > 120 
micromol/l 
Total 














Baseline serum creatinine > 120 micromol/l * serum cystatin C 
rise > 37% Crosstabulation 
Count 
Baseline serum 0 
creatinine > 120 
micromol/l 
Total 















Baseline serum creatinine > 120 micromol/l * Dialysis 
Crosstabulation 
Count 
Baseline serum 0 
















Baseline serum cystatin C > 1.24 mg/l * serum creatinine rise > 25% 
Crosstabulation 
Count 
Baseline serum cystatin 0 
C > 1.24 mg/l 1 
Total 














Baseline serum cystatin C > 1.24 mg/l * serum creatinine rise > 44 
micromol/l Crosstabulation 
Count 
Baseline serum cystatin 0 
C > 1.24 mg/l 1 
Total 














Baseline serum cystatin C > 1.24 mg/l * serum cystatin C rise > 37% 
Crosstabulation 
Count 
Baseline serum cystatin 0 
C > 1.24 mg/l 1 
Total 















Baseline serum cystatin C > 1.24 mg/l * Dialysis Crosstabulation 
Count 
Baseline serum cystatin 0 

















Data for patients undergoing surgery (n=35). Coordinate points for ROC Curve 
baseline calculated creatinine clearance/ serum creatinine/ serum cystatin C * 
outcome dialysis 
Area Under the Curve Baseline Creatinine clearance 














a- Under the nonparametric assumption 
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Area Under the Curve Baseline Serum Creatinine 














a- Under the nonparametric assumption 
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Area Under the Curve Baseline Serum Cystatin C 














The test result variable(s): sicystc has at least one tie between the 
positive actual state group and the negative actual state group. Statistics 
may be biased. 
a. Under the nonparametric assumption 
b. Null hypothesis: true area = 0.5 
143 
Coordinates of the Curve for Baseline serum 
cystatin C in mg/l * Outcome Dialysis 
Test Result Variable(s): sicystc 
Positive if 
Greater Than 
































































































The test result variable(s): sicystc has at least one tie 
between the positive actual state group and the negative 
actual state group. 
a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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Area Under the Curve Baseline Urine Albumin:Creatinine 














a- Under the nonparametric assumption 
D- Null hypothesis: true area = 0.5 
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Coordinates of the curve for Baseline Urine 
Albuminxreatinine in mg/mmol * Outcome Dialysis 
Test Result Variable(s): slalbc 
Positive if 
Greater Than 












































































































a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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APPENDIX I 
Data for patients undergoing surgery (n=35). Coordinate points for ROC Curves for 
T2 urine albumin:creatinine and aGSTrcreatinine * outcome dialysis 
ROC Curve. 







0.00 75 1.00 
1 - Specificity 
Area Under the Curve for T2 Urine albuminxreatinine 














a- Under the nonparametric assumption 
b- Null hypothesis: true area = 0.5 
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T2 Urine GSTcreatinine 
Outcome dialysisi 
1 - Specificity 
Area Under the Curve for T2 urine GSTxreatinine 














a- Under the nonparametric assumption 
D- Null hypothesis: true area = 0.5 
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Coordinates of the Curve for T2 urine 
GSTxreatinine in microgram/mmol 
Test Result Variable(s): s2gstc 
Positive if 
Greater Than 






































































































a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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APPENDIX J 
Data for patients undergoing surgery (n= 35). Coordinate points for RIC Curves for 
peak serum creatinine/ peak cystatin C post op * outcome dialysis 

















a- Under the nonparametric assumption 
b- Null hypothesis: true area = 0.5 
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Coordinates of the Curve Peak serum 
creatinine (S) in micromol/l 
Test Result Variable(s): peak scr 
Positive if 
Greater Than 






































































































a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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Area Under the Curve Peak serum cystatin C * outcome dialysis 














The test result variable(s): Peak S Cyst C has at least one tie between 
the positive actual state group and the negative actual state group. 
Statistics may be biased. 
a. Under the nonparametric assumption 
b- Null hypothesis: true area = 0.5 
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Coordinates of the Curve Peak serum cystatin C in mg/l 
Test Result Variable(s): Peak S Cyst C 
Positive if 
Greater Than 



































































































The test result variable(s): Peak S Cyst C has at least one 
tie between the positive actual state group and the 
negative actual state group. 
a- The smallest cutoff value is the minimum 
observed test value minus 1, and the largest cutoff 
value is the maximum observed test value plus 1. 
All the other cutoff values are the averages of two 
consecutive ordered observed test values. 
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